SlideShare a Scribd company logo
1 of 7
Download to read offline
Letters in Drug Design & Discovery, 2009, 6, 139-145 139
1570-1808/09 $55.00+.00 © 2009 Bentham Science Publishers Ltd.
Presentation of the -Carboxamidophosphonate Arrangement in
Substrate Structures Targeting HIV-1 PR
N.J. Wardle*,a
, H.R. Hudsonb
, R.W. Matthewsb
, C. Nunnb
, C. Vellab
and S.W.A. Bligha
a
Institute for Health Research and Policy; b
Department of Health and Human Sciences, London Metropolitan Univer-
sity, 166-220 Holloway Rd., London, N7 8DB, UK
Received October 27, 2008: Revised December 05, 2008: Accepted December 15, 2008
Abstract: Novel O,O-diethyl 1-benzamido-2,2-biscarbamoylethanephosphonates were synthesised as putative substrates
to HIV-1 PR, to exploit the state of activation of the phosphonate electrophilic function in -carboxamidophosphonate ar-
rangements. O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2-hydroxyethyl)carbamoyl]ethanephosphonate exhibited
moderate anti-HIV activity in vitro (EC50 = 53 μ ), while its depsipeptide analogue; O,O-diethyl 1-benzamido-2,2-
bis[(1S)-N-(1-benzyl-2-{(2’S)-leucinyloxy}ethyl)carbamoyl]ethanephosphonate inhibited HIV-1 PR (IC50 = 31 μ ).
Keywords: -carboxamidophosphonates, HIV-1 PR inhibitors, Anti-HIV agents.
INTRODUCTION
Human immunodeficiency virus type-1 protease (HIV-1
PR) is critical to successful completion of the viral life-cycle,
initiating post-transcriptional cleavage of the viral poly-
protein precursor of gag (p55) and gag-pol (p160) viral pro-
teins, yielding structural proteins and enzymes essential to
virion-maturation. The protease constitutes a homodimer of
two 99-amino-acid-polypeptide monomers, each contribut-
ing an Asp25-Thr26-Gly27 triad to the active-site, located at
a cleft between the two domains as part of a four-stranded
beta turn. Its pivotal role in the viral life cycle has identified
HIV-1 PR as a target for therapeutic intervention, and prote-
ase inhibitors (PIs) have achieved potent inhibition of viral
replication in infected individuals [1-5]. PI candidates have
up to this point employed non-scissile P1-P1 [6] transition-
state isosteres in structures resembling natural substrates to
varying degrees. These have included C2-symmetric struc-
tures, exploiting the protease topology [7-15] (e.g. 1, Moz-
enavir, Fig. 1) both to enhance specificity for HIV-1 PR over
mammalian aspartic proteases and to optimise the P2-P2 / S2-
S2 (and peripheral) interactions critical to binding potency.
Structure-based approaches have achieved potent reversible,
competitive inhibitory profiles in clinical drug combination
(HAART) regimens [16]. Meanwhile, mechanism-based
approaches employing affinity labels have yielded irreversi-
ble, non-competitive inhibitors (e.g. 2, Fig. 1). While corre-
sponding PI candidates have yet to find clinical application
[17-22], the latter approach has the potential to provide po-
tent inhibition at lower concentrations than are required with
non-competitive inhibitors (thereby reducing toxicity).
Various hydrolytic studies have characterised an acute
activation of the -carboxyl/carboxamidophosphonate motif,
and its phosphinate analogue, to nucleophilic displacement at
phosphorus under acidic conditions, either via hydrogen-
bonded [23] or mixed cyclic carboxyl/carboxamidyl-
*Address correspondence to this author at the Institute for Health Research
and Policy, Tower Building, London Metropolitan University, 166-220
Holloway Rd., London, N7 8DB, UK; Tel: +44 207 133 2140; Fax: +44 207
133 2096; E-mail: n.wardle@londonmet.ac.uk
phosphonyl anhydride [24-28] intermediates (Scheme 1).
Analogous activation within an enzyme-inhibitor (EI) com-
plex of HIV-1 PR could offer scope for interaction with
various enzymatic residues, subject to the positioning of the
inhibitor’s “warhead” [29] function. Potential interactions
would include covalent adduct formation (e.g. with Thr
26/26’ or Thr31/31’ residues), or alternatively sequestration
of enzymatic water (e.g. the water molecule hydrogen-
bonded to Ile50/50’ binding-flap residues) in hydrolysis. The
water molecule specified in parenthesis is critical to ES bind-
ing interactions [3,30], and its functional replacement has
previously featured as a target for inhibitor design [11-16] in
order to exploit the entropic gain arising from liberation of
the protein-bound water to bulk solvent [31]. In the context
of the titled structures, hydrolytic sequestration of this water
molecule could release the alcohol by-product of displace-
ment to bulk solvent, while retaining hydrogen-bonding in-
teractions with Ile50/50’ residues through the modified
phosphonate function. Therefore, the titled compounds were
developed to present the above motif in pseudo-C2-
symmetric, peptidomimetic structures commensurate with
the binding criteria of HIV-1 PR.
1 Mozenavir
N N
O
HO OH
N
H
N
N
H
O
O
S
O
N
S
O
O
O O
2
H2N NH2
Fig. (1). Examples of reversible (1) and irreversible (2) inhibitors of
HIV-1 PR.
140 Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 Wardle et al.
RESULTS AND DISCUSSION
Modelling
“Molegro” virtual docking experiments indicated flexi-
ble docking of ligand 3 (Scheme 2) within the negatively
charged active-site binding pocket of the protease dimer, and
hydrogen-bonding interactions were exhibited in top-ranked
poses, between components of the N-(1-phenyl-2-
hydroxyethyl)carbamoyl functions of 3 and the Gly27 and
Gly48 enzymatic residues respectively (of 1.7Å and 2.3Å
distance in the lowest energy conformation, Fig. 2). The
lowest energy conformation also exhibits one -
biscarbamoyl oxo-function of 3 proximal (2.1Å) to the ac-
tive-site Asp25 carboxyl, and suggests scope for interaction
between the ligand’s phosphonate function and the Ile50/50 -
bound structural water molecule described above. With re-
spect to enzymatic Ile50/50 N-atoms, the ligand P=O phos-
phorus atom is placed at 6.3Å and 6.0Å distances respec-
tively and the corresponding oxygen atom at 5.1Å and 4.8Å
distances.
Chemistry
The synthetic route followed for the titled O,O-diethyl 1-
benzamido-2,2-biscarbamoyl-ethanephosphonates is illus-
trated in Scheme 2. AdN-E reaction between diethyl
ethoxymethylenemalonate (4) and benzamide at 180-200o
C
over 6 h gave diethyl benzamidomethylenemalonate (5,
40%). Thereafter, a base-catalysed Michael addition of di-
ethyl phosphite across the olefinic function therein [32,33]
generated O,O-diethyl benzamido[diethoxyphosphinyl]
methyl malonate (6, 82%) from which the biscarbamoyl
structure would be constructed by aminolysis. The state of
activation towards nucleophilic substitution recorded in eno-
lizable -dicarbonyl ester systems [34-36] led to an anticipa-
tion of desired chemoselectivity of substitution, despite the
presence in malonate 6 of two functions (i.e. carboxylate and
phosphonate) potentially reactive to the same reagents and
catalysts. Accordingly, desired bis[N-(1-phenyl-2-hydroxy-
ethyl)carbamoyl] derivative 3 was generated in a methanolic
medium in 18% yield from 6 using a minor excess of (2S)-
phenylalaninol at maximum practicable concentration and
mildly elevated temperature (45-55o
C, 14 days). Use of simi-
lar conditions in preliminary procedures involving benzy-
lamine and straight-chain alkanolamine reagents abnegated
P
O
O
RO
X
intramolecular
H-bonded
intermediates
mixed cyclic carboxyl/
carboxamidyl-phosphonyl
anhydride
X = O, N R''R'''
P
O
O
O
RO
O
H or
P
O
O
O
RO
H
OR
R
P
R'
O
RO
RO
O
R = alkyl
R' = OH, NR''R'''
reactive
intermediate
P
R'
O
HO
HO
O
Scheme 1. Accelerated hydrolysis of phosphonate functions via active intermediates.
Fig. (2). Lowest docked energy conformation of ligand 3 showing
hydrogen bonding interactions.
Presentation of the -Carboxamidophosphonate Arrangement Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 141
chemoselectivity, necessitating procedures conducted at
room temperature to generate the corresponding bis-N-
carbamoyl derivatives. Significant excess of amine reagent
invariably resulted in concomitant mono-dealkylation of the
phosphonate function, while use of organonitrogen nucleo-
philic/base catalysts (i.e. aniline, pyridine, imidazole etc.)
also diminished chemoselectivity unacceptably.
In addition to their function as putative binding determi-
nants, the hydroxyl functions of 3 permit modification of
lipophilicity/water-solubility characteristics via derivatiza-
tion to depsipeptides - an established method of enhancing
drug bioavailability. DCC/DMAP-mediated coupling [37]
furnished enantiopure Cbz-leucinyl derivative 7 (66%),
which was deprotected by catalytic hydrogenolysis at atmos-
pheric pressure over Pd/C (5% w/w, CAUTION) and iso-
lated as dihydrochloride salt 8 of the enantiopure depsipep-
tide (72%).
4 R = EtO
5 R = BzNH
i
5, ii
3 R' = OH
7 R' = O-(2S)-Leu-Cbz
8 R' = O-(2S)-Leu-NH2.HCl
iv
v
iii
6
EtO OEt
O O
R
OEtEtO
OO
NH(EtO)2P
O
O
R'
H
N
H
N
R'
O O
(EtO)2P NH
O
O
Scheme 2. (i) BzNH2, ; (ii) HP(O)(OEt)2, NaOEt (cat), ; (iii) (S)-
phenylalaninol (2.1 eqv.), 45-55o
C; (iv) Cbz-leu-OH, DCC, DMAP
(cat.); (v) Pd/C (5%), H2, then dry HCl/Et2O.
Biological Activity
Compounds were tested for in vitro anti-HIV activity at
the National Institutes of Health, USA (NIH) against the T-
cell line adapted isolate HIV-1LAI/3B (3B) in CEM-SS cells
using a standard XTT assay [38]. Compound 3 was found to
be moderately active (EC50 = 53 μM), while attempts to en-
hance cellular uptake through development of depsipeptide
structures resulted in a loss of in vitro activity in leucinyl
derivatives 7 and 8 (EC50 > 200μM). However, in HIV-1 PR
binding studies, the binding of 8 proved superior to that of 3
(IC50 = 31 μM and >50 μM respectively) [39].
CONCLUSIONS
In summary, a putative ligand to HIV-1 PR, i.e. 3, consti-
tuting a -carboxamidophosphonate arrangement, has been
developed; exhibiting moderate anti-HIV activity in vitro.
While the enhanced HIV-1 PR binding of depsipeptide 8
compared with that of 3 is explicable in terms of alternative
binding modes and participation of the leucinyl function in
EI interactions, the lack of anti-HIV activity of 8 (and 7) in
vitro compared with 3 has yet to be explained, although a
correlation with the relative efficacies of intracellular trans-
port of these compounds may be possible.
EXPERIMENTAL SECTION
General
NMR spectra were recorded at ambient temperature (un-
less otherwise stated), on a Bruker AM-250 (1
H, 1
H-1
H
COSY, 250.13 MHz; 13
C, 135-DEPT, 62.90 MHz; 31
P,
101.26 MHz) or Bruker Avance-500 (1
H, 1
H-1
H COSY,
500.13 MHz; 13
C, 135-DEPT, 125.77 MHz; 31
P, 202.45
MHz) spectrometer in pulse Fourier transform (pFt) mode.
All 13
C and 31
P NMR spectra are 1
H-broad-band decoupled.
1
H and 13
C NMR spectra were referenced internally to
Me4Si. Aqueous phosphoric acid (85% H3PO4) was used as
the external reference for 31
P NMR spectra. Infrared spectra
were recorded on a Bruker Vector 22 FT-IR or Nicolet IR-
100 FT-IR spectrophotometer, with samples prepared as
16mm diameter KBr discs. Mass spectrometry was per-
formed either using a Kratos Profile HV3 mass spectrometer
in “Liquid Secondary Ionization Mass Spectrometry” mode
(employing glycerol as a matrix), or a Finnigan 710C spec-
trometer with an electrospray source in positive ion mode.
Melting points were obtained on an Electrothermal Eng. Ltd.
digital melting-point apparatus, and are uncorrected. A Carlo
Erba 1108 Elemental Analyser was used for C, H and N mi-
croanalyses. TLC was performed on precoated silica plates
(Whatman Al Sil G/UV, 250 μm layer) using
CH2Cl2/MeOH, 50:3 (v/v) as solvent eluent; denoted “sys-
tem A” in the experimental section.
Reagents were used as purchased. (2S)-Cbz-Leucine was
prepared according to the methodology of Zervas et al. [40].
Drying (and storage) of solvents when necessary were car-
ried out according to established methods [41].
Synthesis
Diethyl Benzamidomethylenemalonate (5). A suspen-
sion of benzamide (78.74 g, 650.0 mmol) in diethyl
ethoxymethylenemalonate 4 (140.55 g, 650.0 mmol) was
heated at 180-200o
C in a distillation apparatus fitted with a
Dean-Stark trap, until one equivalent of ethanol had been
collected (6 h). When cool, the oily mixture was washed
with petroleum ether (3x150 cm3
), triturated in petroleum
ether (300 cm3
) and left to crystallize in the ether over sev-
eral days. The solid formed was isolated, and recrystalliza-
tion from 99IMS/petroleum ether (1:1) solution yielded 5 as
a waxy, yellow solid (76.23 g, 40%). Rf 0.87 (system A, u.v.
abs.), mp 42-45o
C; IR: 3446, 1724, 1706, 1666, 1604, 1453,
1377, 1267, 1246, 1216, 1077, 1068, 1059; H(CDCl3): 1.35,
1.40 [6H, 2x t, J 7.1, 2x CH3]; 4.28, 4.36 [4H, 2x q, J 7.1, 2x
CH2]; 7.40-7.68 [3H, m’s, m,p-Ar-H]; 7.975, 7.98 [2H, 2x d,
142 Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 Wardle et al.
J 7.3, 7.0 resp., o-Ar-H]; 8.78 [1H, d, J 11.8, C=CH]; 12.02
[1H, br.d., J 11.8, NH]; C(CDCl3): 14.17, 14.27 [2x CH3];
60.88, 61.41 [2x CH2]; 102.74 [HC=C]; 127.54, 128.00,
128.60, 129.12, 131.46 (ipso), 133.61 [Ar-C]; 146.94
[HC=C]; 164.26, 164.47, 167.98 [C=O’s]; MS (LSIMS): 292
(81%, [MH]+
). Anal. Calcd for C15H17NO5: C, 61.85; H,
5.88; N, 4.81%. Found: C, 62.07; H, 6.00; N, 4.81%.
Diethyl Benzamido[diethoxyphosphinyl]methyl Malo-
nate (6). A vigorously stirred reaction mixture of 5 (58.50 g,
200.0 mmol) in freshly distilled diethyl phosphite (30.38g,
220.0 mmol) was heated to 65o
C, at which time heating was
stopped as ethanolic sodium ethoxide solution was added
dropwise (~ 1 M, 1 cm3
). An exothermic reaction was ob-
served immediately, the reaction temperature rising to
100o
C, and the temperature was maintained at 90-95o
C for
2.5 h after the exothermic reaction had subsided. Diethyl
ether (20 cm3
) was added to the cooled mixture and the re-
sulting solution was immediately filtered. Material crystal-
lized from the filtrate over several days was isolated in two
crops and washed with diethyl ether (20 cm3
, dropwise) to
leave 6 as a crystalline white solid (70.38 g, 82%). Rf 0.52
(system A, I2 vis.), mp 86-90o
C; IR: 3274, 1700, 1671, 1545,
1539, 1321, 1311, 1245, 1227, 1047, 1015, 983, 966;
H(CDCl3): 1.21, 1.29, 1.34 [12H, 3x t, J 7.1, 7.1, 7.2 resp.,
4x CH3]; 4.02 [1H, dd, J1 5.3, J2 3.1, C H]; 4.08-4.39 [8H,
m’s, 4x CH2]; 5.39 [1H, ddd, J1 17.9, J2 9.8, J3 3.1, C H];
7.40-7.53 [3H, m’s, m,p-Ar-H]; 7.81, 7.82 [2H, 2x d, J 6.8,
6.7 resp., o-Ar-H]; 7.89 [1H, br.d, J ~9.8, NH]; C(CDCl3):
13.93, 13.97 [2x C(O)OCH2CH3]; 16.33, 16.39 [2x d, J 5.7,
5.5 resp., P(OCH2CH3)2]; 45.76 [d, J 161.8, C ]; 50.59 [d, J
5.1, C ]; 62.12, 62.45 [2x C(O)OCH2]; 63.16, 63.33 [2x d, J
6.6, 6.9 resp., P(OCH2CH3)2]; 127.14, 127.81, 128.59,
128.68, 131.86 [o,m,p-Ar-C], 133.73 [ipso-Ar-C]; 166.45,
166.69, 168.62 [3x d, J 3.8, 18.1, 2.8 resp., C=O’s];
P(CDCl3): 21.06; MS (LSIMS): 430 (100%, [MH]+
). Anal.
Calcd for C19H28NO8P: C, 53.15; H, 6.57; N, 3.26%. Found:
C, 53.46; H, 6.67; N, 3.17%.
O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2-hyd-
roxyethyl)carbamoyl]ethanephosphonate (3). A methanolic
solution (10 cm3
) of malonate 6 (6.87 g, 16.0 mmol) and
(2S)-2-amino-3-phenyl-1-propanol (5.41 g, 35.8 mmol, ~ 2.1
equiv.) was stirred at 45-55o
C for 14 days (monitored by
TLC; solvent system A) under anhydrous conditions. The
reaction mixture was evaporated in vacuo, redissolved in
ethyl acetate (200 cm3
), and the solution was washed with
deionised water (2x100 cm3
), 0.2N HCl solution (2x100
cm3
), sat’d NaHCO3 solution (2x100 cm3
) and sat’d brine
(2x100 cm3
) respectively. The organic phase was dried over
MgSO4 and evaporated in vacuo. Column chromatography
over silica (CH2Cl2/MeOH; 89:11 v/v) yielded a clear oil
from which a white solid was crystallized in methanol (5
cm3
). Washing of the isolated solid with acetone and diethyl
ether yielded 3 as a white powder (1.87 g, 18%). Rf 0.33
(system A, u.v. abs.), mp 186-187o
C; IR: 3419, 3305, 1700,
1692, 1672, 1652, 1539, 1329, 1252, 1232, 1052, 1032, 971;
H(DMSO-d6): 1.15, 1.21 [6H, 2x t, J 6.9, 7.0 resp., 2x
CH3)]; 2.58-2.82 [4H, m’s, 2x CH2Ph]; 3.08-3.38 [4H, 2x m,
2x CH2OH]; 3.78 [1H, dd, J1J2 7.7, C H]; 3.72-4.07 [6H,
m’s, P(OCH2CH3)2 and 2x NCHBn]; 4.78, 4.81 [2H, 2x t, J
5.3, 5.6 resp., 2x OH]; 5.08 [1H, ddd, J1 14.7, J2 8.2, J3 7.7,
C H]; 7.13-7.29 [10H, m’s, Ar-H {Bn}]; 7.43-7.58 [3H, m’s,
m,p-Ar-H {Bz}]; 7.73 [1H, d, J 8.2, NHCH]; 7.75 [2H, d, J
8.1, o-Ar-H {Bz}]; 8.00 [1H, d, J 8.2, NHCH]; 8.68 [1H, d, J
8.2, BzNH]; C(DMSO-d6): 16.14 [2x d, J 5.9, 2x CH3];
35.89, 36.12 [2x CH2Ph]; 46.39 [d, J 158.5, C ]; 51.46 [d, J
5.6, C ]; 52.51, 52.64 [2x CHBn]; 61.03, 61.43 [2x HOCH2];
62.04, 62.31 [2x d, J 6.6, 6.9 resp., P(OCH2CH3)2]; 125.91,
127.00, 128.05, 128.10, 128.31, 128.96, 129.10, 131.30
[o,m,p-Ar-C], 134.08 [ipso-Ar-C {Bz}]; 138.59, 138.63 [2x
ipso-Ar-C {Bn}]; 165.59, 165.68, 167.12 [3x d, J 5.5, 11.3,
10.2 resp., C=O’s]; P(DMSO-d6): 23.59; MS (LSIMS): 641
(100%, [MH]+
). Anal. Calcd for C33H42N3O8P: C, 61.96; H,
6.62; N, 6.57%. Found: C, 61.96; H, 6.73; N, 6.46%.
O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2-
{(2’S)-N-[benzyloxycarbonyl]leucinyloxy}ethyl) carbamoyl]-
ethanephosphonate (7). A dichloromethane solution (25
cm3
) containing DCC (0.70 g, 3.4 mmol), (2S)-Cbz-leucine
(0.83 g, 3.1 mmol), phosphonate 6 (0.83 g, 1.3 mmol) and
DMAP (0.06 g, 0.5 mmol) was stirred at 0o
C for 30 min, and
at rt for 72 h thereafter, with moisture excluded. The mixture
was filtered, the isolated solid was washed with dichloro-
methane (3x20 cm3
), and the combined filtrate and washings
were evaporated in vacuo (40o
C). An ethyl acetate solution
of the residue (250 cm3
, filtered after 3 days) was washed
with ice-cold 1N HCl solution (2x250 cm3
), sat’d NaHCO3
solution (2x250 cm3
) and sat’d brine (2x250 cm3
) respec-
tively, dried over MgSO4, and evaporated in vacuo to leave a
semi-solid residue. Column chromatography over silica
(CH2Cl2/MeOH; 91:9 v/v) yielded 7 as a clear glass (0.97 g,
66%). Rf 0.40 (system A, u.v. abs.), softening pt 56-59o
C;
IR: 3413, 3291, 2957, 1749, 1724, 1676, 1532, 1243, 1048,
1026, 978; H(DMSO-d6): 0.88, 0.90 [12H, 2x d, J 6.2, 6.3
resp., 4x CH3 {Leu}]; 1.15, 1.20 [6H, 2x t, J 7.0,
P(OCH2CH3)2]; 1.43-1.82 [6H, m’s, 2x CHCH2Me2]; 2.55-
2.74 [4H, m’s, 2x CH2Ph {Bn}]; 3.77-3.89 [4H, 2x m, 2x
CH2OLeu]; 3.80-3.90 [1H, m, C H]; 3.89-4.11 [4H, m,
P(OCH2CH3)2]; 4.08-4.29 [4H, m, 2x NCHBn and 2x NCH
{Leu}]; 5.03-5.14 [1H, m, C H]; 5.03, 5.04 [4H, 2x s, 2x
CH2 {Cbz}]; 7.15-7.35 [20H, m’s, Ar-H {Cbz, Bn}]; 7.41-
7.54 [3H, m, m,p-Ar-H {Bz}]; 7.74 [2H, d, J 7.3, o-Ar-H
{Bz}]; 7.79, 7.97, 8.12 [4H, 3x d, J 8.3, 7.8, 7.8 resp., 4x
NHCH]; 8.72 [1H, d, J 9.1, BzNH]; C(DMSO-d6): 16.10 [d,
J 5.2, P(OCH2CH3)2]; 20.97, 22.63 [4x CH3 {Leu}]; 24.15
[2x CHMe2]; 35.90, 36.00 [2x CH2 {Leu}]; 39.33 [2x CH2
{Bn}]; 46.44 [d, J 175.5, C ]; 49.04 [2x NCHLeu]; 51.37
[C ]; 52.18 [2x NCHBn]; 61.97, 62.24 [2x d, J 6.7,
P(OCH2CH3)2]; 64.05, 64.37 [2x CH2OLeu]; 65.43 [CH2
{Cbz}]; 126.17, 126.91, 127.56, 127.69, 128.19, 128.33,
128.83, 128.95 [o,m,p-Ar-C], 133.90 [ipso-Ar-C {Bz}];
136.72, 136.74, 137.46 [ipso-Ar-C {Cbz, Bn}]; 156.03,
156.06 [C=O’s {Cbz}]; 165.65, 165.71, 165.87, 166.98,
167.13 [C=O’s, {Cbm, Bz}]; 172.31, 172.41 [C=O’s, {es-
ter}]; P(DMSO-d6): 23.31; MS (LSIMS): 1133 (63%,
[MH]+
). Anal. Calcd for C61H74N5O14P: C, 64.71; H, 6.59; N,
6.19%. Found: C, 64.94; H, 6.65; N, 6.09%.
O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2-
{(2’S)-leucinyloxy}ethyl)carbamoyl]-ethanephosphonate
Di-hydrochloride Salt (8). Pd/C (5% Pd w/w, 0.51 g, CAU-
TION; pyrophoric in air) was added to a suspension of
phosphonate ester 7 (0.29 g, 0.25 mmol) in absolute ethanol
(50 cm3
) at 0o
C under an atmosphere of N2. The mixture was
stirred under N2 for 10 min and under a stream of dry H2 gas
Presentation of the -Carboxamidophosphonate Arrangement Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 143
for 3 h thereafter (1.5 h at rt, and 1.5 h at 50o
C), then filtered
through a column of Celite 521 filter agent under N2. The
filtrate was evaporated in vacuo, redissolved in diethyl ether
(50 cm3
, seeded with methanol), and bubbled with dry HCl
gas for 30 min at 0o
C. Evaporation in vacuo, and trituration
of the residue in petroleum ether afforded 8 as a cream-white
powder (0.17 g, 72%), mp 134-136o
C; IR: 3431, 3300, 2960,
1752, 1686, 1533, 1221, 1048, 1026, 977; H(DMSO-d6):
0.88, 0.90 [12H, 2x d, J 5.9, 4x CH3 {Leu}]; 1.12, 1.18 [6H,
2x t, J 7.1, 7.2, P(OCH2CH3)2]; 1.45-1.93 [6H, m’s, 2x
CH2CHMe2]; 2.70-3.00 [4H, m’s, 2x CH2Ph]; 3.70-4.38
[13H, m’s, P(OCH2CH3)2, C H, 2x NCHBn, 2x NCH {Leu}
and 2x CH2OLeu]; 5.11 [1H, m, C H]; 7.18-7.40 [10H, m,
Ar-H {Bn}]; 7.43-7.54 [3H, m, m,p-Ar-H {Bz}]; 7.82 [2H,
d, J 7.3, o-Ar-H {Bz}]; 8.20-9.05 [~9H, m’s, 7x NH and 2x
HCl]; C(DMSO-d6): 16.17 [d, J 2.7, P(OCH2CH3)2]; 21.89,
21.97 [4x CH3 {Leu}]; 23.66 [2x CHMe2]; 35.83, 36.11 [2x
CH2 {Leu}]; 38.71 [2x CH2 {Bn}]; 45.96 [d, J 157.2, C ];
49.25, 49.88 [4x NCH]; 50.67 [C ]; 62.00, 62.24 [2x d, J 7.0,
6.6 resp., P(OCH2CH3)2]; 65.71, 65.88 [2x CH2OLeu];
126.22, 127.11, 128.22, 128.92, 128.99, 131.27 [o,m,p-Ar-
C], 133.95 [ipso-Ar-C {Bz}]; 137.85, 137.94 [ipso-Ar-C
{Bn}]; 163.21, 165.46, 165.96, 166.07, 167.02, 169.09
[C=O’s]; P(DMSO-d6): 23.29, 24.87 (95:5 resp., rt)
22.70 (100o
C); MS (Es-MS): 866 (100%, [MH]+
{free
amine}); MS (LSIMS): 866 (32%, [MH]+
{free amine}).
Anal. Calcd for C45H64N5O10P.2HCl: C, 57.56; H, 6.87; N,
7.46%. Found: C, 57.41; H, 6.88; N, 7.58%.
Computational Details
The X-ray crystal structure of HIV-1 protease (PDB code
1HSG) was used as a model for the HIV-1 protease. The 3-D
coordinates for the structure of ligand 3, including hydrogen
atoms, were generated using Chem3D Ultra version 10.0
(ChemOffice 2006, CambridgeSoft Corporation) and energy
minimised. Modelling of the ligand into the active site of
HIV-1 protease was carried out using the Molegro virtual
docker which utilises the MolDock algorithm [42]; a hybrid
search algorithm called “guided differential evolution”
which combines the differential evolution optimisation tech-
nique with a cavity prediction algorithm. The docking scor-
ing function of MolDock is based upon a piecewise linear
potential [43], and the docking procedure was randomized
with a minimum of 10 runs and 5000 iterations. The best five
poses (ligand orientation) generated were recalculated and
re-ranked by analyzing the energy scores, binding affinities,
and ligand-residue (H-bond) interactions, and the top-ranked
pose was visualized using the Molegro virtual docker visu-
alization software.
Anti-HIV Activity: XTT Assay
The XTT assay was performed at NIH as described [38].
Briefly, stock solutions of the compounds were prepared in
DMSO and serial half log10 dilutions (10-3
M to 10-7
M) added
to 3B-infected CEM-SS cells. After 6 days, the tetrazolium
salt XTT and phenazine methosulfate were added to the
cells, and the assay incubated to allow formazin colour de-
velopment by metabolically active viable cells. Colour de-
velopment was analysed spectrophotometrically to quantitate
formazin production in individual wells. Compound-treated,
virus-infected wells were compared both with untreated,
virus-infected wells and with controls. Uninfected, treated
cells served as a control for compound-induced cytotoxicity
while AZT-treated, infected cells served as a positive control
for protection from 3B-induced cell death. The concentration
protecting 50% of cells (EC50) from 3B-induced cell death
was calculated.
ACKNOWLEDGEMENTS
We thank Mr. J. Crowder for running NMR spectra, Mr.
W. Dissanayake for running mass spectra, and Mr. S. Boyer
for running C, H, N microanalysis. We also thank the
Thrombosis Research Institute for the mass spectrometry
performed on compound 8. Dr T. Lowinger of Bayer AG,
Wuppertal, Germany is thanked for bioevaluation against
HIV-1 PR; and NIH, Bethesda, USA, is also thanked for
evaluating anti-HIV activity.
ABBREVIATIONS
abs = absorption
AdN-E = addition-elimination
Asp = aspartic acid
Bn = benzyl
br = broad
Bz = benzoyl
Cbz = carbobenzyloxy
Cbm = carbamoyl
COSY = correlated spectroscopy
DCC = N,N-dicyclohexylcarbodiimide
DEPT = distortionless enhancement by polarisation
transfer
DMAP = 4-dimethylaminopyridine
DMSO = dimethyl sulfoxide
EI = enzyme-inhibitor complex or interaction
ES = enzyme-substrate complex or interaction
Es-MS = electrospray mass spectrometry
Gly = glycine
HAART = “highly active anti-retroviral therapy;”
imp = impurity
99IMS = industrial methylated spirits (denatured etha-
nol)
Leu = leucine
LSIMS = liquid secondary ionization mass spectrome-
try
resp = respectively
rt = room temperature
sat’d = saturated
Thr = threonine
vis = visualization
144 Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 Wardle et al.
XTT- = 2,3-bis[2-methoxy-4-nitro-5-sulfo-phenyl]-5-
[(phenylamino)carbonyl]-2H-tetrazolium
hydroxide
o-, m-, p- = ipso- are used according to the standard
convention for aromatic substituents
C and C = denote carbons of the central ethane motif at
positions and respectively to phospho-
rus.
REFERENCES AND NOTES
[1] Deeks, S.G.; Smith, M.; Holodniy, M.; Kahn, J.O. HIV-1 Protease
Inhibitors. A review for clinicians. J. Am. Med. Assoc., 1997, 277,
145-153.
[2] Dougherty, W.G.; Semler, B.L. Expression of virus-encoded prote-
inases: Functional and structural similarities with cellular enzymes.
Microbiol. Rev., 1993, 57, 781-822.
[3] Wlodawer, A.; Erickson, J.W. Structure-based inhibitors of HIV-1
Protease. Annu. Rev. Biochem., 1993, 62, 543-585.
[4] Leung, D.; Abbenante, G.; Fairlie D.P. Protease Inhibitors: Current
status and future prospects. J. Med. Chem., 2000, 43, 305-341.
[5] De Clercq, E. New anti-HIV agents and targets. Med. Res. Rev.,
2002, 22, 531-565.
[6] For oligopeptide residue notation see; Schechter, I.; Berger, A. On
the size of the active site in proteases. Biochem. Biophys. Res.
Commun., 1967, 27, 157-162.
[7] Kempf, D.J.; Codacovi, L.; Wang, X.C.; Kohlbrenner, W.E.;
Wideburg, N.E.; Saldivar, A.; Vasavanonda, S.; Marsh, K.C.;
Bryant, P.; Sham, H.L.; Green, B.E.; Betebenner, D.A; Erickson,
J.; Norbeck, D.W. Symmetry-based inhibitors of HIV Protease.
Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-
hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.
J.Med. Chem., 1993, 36, 320-330.
[8] Alterman, M.; Björsne, M.; Mühlman, A.; Classon, B.; Kvarn-
ström, I.; Danielson, H.; Markgren, P-O.; Nillroth, U.; Unge, T.;
Hallberg, A.; Samuelsson, B. Design and synthesis of new potent
C2-symmetric HIV-1 Protease inhibitors. Use of L-mannaric acid as
a peptidomimetic scaffold. J. Med. Chem., 1998, 41, 3782-3792.
[9] For review of phosphinic acid-based C2-symmetric inhibitors see
Section 5.1 of; Wardle, N.J.; Bligh, S.W.A.; Hudson, H.R. Organo-
phosphorus Chemistry: Therapeutic intervention in mechanisms of
viral and cellular replication. Curr. Org. Chem., 2005, 9, 1803-
1828.
[10] DMP-450 (Mozenavir) - ; Hodge, C.N.; Aldrich, P.E.; Bacheler,
L.T.; Chang, C-H.; Eyermann, C.J.; Garber, S.; Grubb, M.; Jack-
son, D.A.; Jadhav, P.K.; Korant, B.; Lam, P.Y.S.; Maurin, M.B.;
Meek, J.L.; Otto, M.J.; Rayner, M.M.; Reid, C.; Sharpe, T.R.;
Shum, L.; Winslow, D.L.; Erickson-Viitanen, S. Improved cyclic
urea inhibitors of the HIV-1 Protease: Synthesis, potency, resis-
tance profile, human pharmacokinetics and X-ray crystal structure
of DMP 450. Chem. Biol., 1996, 3, 301-314.
[11] DMP-323 - ; Lam, P.Y.S.; Ru, Y.; Jadhav, P.K.; Aldrich, P.E.;
DeLucca, G.V.; Eyermann, C.J.; Chang, C-H.; Emmett, G.; Holler,
E.R.; Daneker, W.F.; Li, L.; Confalone, P.N.; McHugh, R.J.; Han,
Q.; Li, R.; Markwalder, J.A.; Steitz, S.P.; Sharpe, T.R.; Bacheler,
L.T.; Rayner, M.M.; Klabe, R.M.; Shum, L.; Winslow, D.L.; Korn-
hauser, D.M.; Jackson, D.A.; Erickson-Viitanen, S.; Hodge, C.N.
Cyclic HIV Protease Inhibitors: Synthesis, conformational analysis,
P2/P2’structure-activity relationship, and molecular recognition of
cyclic ureas. J. Med. Chem., 1996, 39, 3514-3525.
[12] Nugiel, D.A.; Jacobs, K.; Worley, T.; Patel, M.; Kaltenbach III,
R.F.; Meyer, D.T.; Jadhav, P.K.; De Lucca, G.V.; Smyser, T.E.;
Klabe, R.M.; Bacheler, L.T.; Rayner, M.M.; Seitz, S.P. Preparation
and structure-activity relationship of novel P1/P1’-substituted cy-
clic urea-based human immunodeficiency virus type-1 protease in-
hibitors. J. Med. Chem., 1996, 39, 2156-2169.
[13] Jadhav, P.K.; Ala, P.; Woerner, F.J.; Chang, C-H.; Garber, S.S.;
Anton, E.D.; Bacheler, L.T. Cyclic urea amides: HIV-1 Protease
with low nanomolar potency against both wild type and protease
inhibitor resistant mutants of HIV. J. Med. Chem., 1997, 40, 181-
191.
[14] Han, Q.; Chang, C-H.; Li, R.; Ru, Y.; Jadhav, P.K.; Lam, P.Y.S.
Cyclic HIV-Protease Inhibitors: Design and synthesis of orally
bioavailable pyrazole P2/P2’cyclic ureas with improved potency. J.
Med. Chem., 1998, 41, 2019-2028.
[15] Ax, A.; Schaal, W.; Vrang, L.; Samuelsson, B.; Hallberg, A.; Kar-
lén, A. Cyclic sulfamide HIV-1 Protease inhibitors with sidechains
spanning from P2/P2’ to P1/P1’. Bioorg. Med. Chem., 2005, 13,
755-764; and references cited.
[16] De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Virol.,
2004, 30, 115-133.
[17] Meek, T.D.; Dayton, B.D.; Metcalf, B.W.; Dreyer, G.B.; Strickler,
J.E.; Gorniak, J.G.; Rosenberg, M.; Moore, M.L.; Magaard, V.W.;
DeBouck, C. Human immunodeficiency virus 1 protease expressed
in Escherichia Coli behaves as a dimeric aspartic protease. Proc.
Natl. Acad. Sci. USA, 1989, 86, 1841-1845.
[18] Park, C.; Koh, J.S.; Son, Y.C.; Choi, H-il.; Lee, C.S.; Choy, N.;
Moon, K.Y.; Jung, W.H.; Kim, S.C.; Yoon, H. Rational design of
irreversible psuedo-C2-symmetric HIV-1 Protease inhibitors.
Bioorg. Med. Chem. Lett., 1995, 5, 1843-1848.
[19] Yu, Z.; Caldera, P.; McPhee, F.; De Voss, J.J.; Jones, P.R.;
Burlingame, A.L.; Kuntz, I.D.; Craik, C.S.; Ortiz de Montellano,
P.R. Irreversible inhibition of the HIV-1 Protease: Targeting alky-
lating agents to the catalytic aspartate groups. J. Am. Chem. Soc.,
1996, 118, 5846-5856.
[20] Choy, N.; Choi, H-il.; Jung, W.H.; Kim, C.R.; Yoon, H.; Kim,
S.C.; Lee, T.G.; Koh, J.S. Synthesis of irreversible HIV-1 Protease
inhibitors containing sulfonamide and sulfone as amide bond isos-
teres. Bioorg. Med. Chem. Lett., 1997, 7, 2635-2638.
[21] De Voss, J.J.; Sui, Z.; DeCamp, D.L.; Salto, R.; Babé, L.M.; Craik,
C.S.; Ortiz de Montellano, P.R. Haloperidol-based irreversible in-
hibitors of the HIV-1 and HIV-2 Proteases. J. Med. Chem., 1994,
37, 665-673.
[22] Zutshi, R.; Chmielewski, J. Targeting the dimerization interface for
irreversible inhibition of HIV-1 Protease. Bioorg. Med. Chem.
Lett., 2000, 10, 1901-1903.
[23] Gordon, M.; Notaro, V.A.; Griffin, C.E. Phosphonic acids and
esters. VII. Intramolecular electrophilic catalysis of phosphonate
ester hydrolysis by neighboring carboxyl. J. Am. Chem. Soc., 1964,
86, 1898-1899.
[24] Jacobsen, N.E.; Bartlett, P.A. Cyclic phosphonic-carboxylic imides
and anhydrides as reactive intermediates. 1. Rearrangement and
solvolysis of N-[amino(methyl)phosphinyl]-L-phenylalanine de-
rivatives. J. Am. Chem. Soc., 1983, 105, 1613-1619.
[25] Jacobsen, N.E.; Bartlett, P.A. Cyclic phosphonic-carboxylic imides
and anhydrides as reactive intermediates. 2. Solvolysis of N-
[hydroxy(methyl)phosphinothioyl]-L-phenylalanine. J. Am. Chem.
Soc., 1983, 105, 1619-1626.
[26] Georgiadis, D.; Dive, V.; Yiotakis, A. Synthesis and comparative
study on the reactivity of peptidyl-type phosphinic esters: In-
tramolecular effects in the alkaline and acidic cleavage of methyl
-carboxyphosphinates. J. Org. Chem., 2001, 66, 6604-6610.
[27] Reiter, L.A.; Jones, B.P. Amide-assisted hydrolysis of -
carboxamido-substituted phosphinic acid esters. J. Org. Chem.,
1997, 62, 2808-2812.
[28] Kluger, R.; Chan, J.L.W. Amide-phosphate interactions: Acid
catalysis in amide-assisted hydrolysis of phosphonate esters. J. Am.
Chem. Soc., 1976, 98, 4913-4917; and references cited.
[29] Walsh, C. Suicide Substrates: Mechanism-based enzyme inactiva-
tors. Tetrahedron, 1982, 38, 871-909.
[30] Okimoto, N.; Tsukui, T.; Kitayama, K.; Hata, M.; Hoshino, T.;
Tsuda, M. Molecular dynamics study of HIV-1 Protease-substrate
complex: Roles of the water molecules at the loop structures of the
active site. J. Am. Chem. Soc., 2000, 122, 5613-5622.
[31] Dunitz, J.D. The entropic cost of bound water in crystals and bio-
molecules. Science, 1994, 264, 670.
[32] Soroka, M.; Mastalerz, P. The synthesis of phosphonic and
phosphinic analogs of aspartic acid and asparagine. Rocz. Chem.,
1976, 50, 661-666.
[33] Merrett, J.H.; Spurden, W.C.; Thomas, W.A.; Tong, B.P.; Whit-
combe, I.W.A. The synthesis and rotational isomerism of 1-amino-
Presentation of the -Carboxamidophosphonate Arrangement Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 145
2-imidazol-4-ylethylphosphonic acid [Phosphonohistidine, His(P)]
and 1-amino-2- imidazol-2-ylethylphosphonic acid [Phosphonoiso-
histidine, Isohis(P)]. J. Chem. Soc. Perkin Trans. I, 1988, 61-67.
[34] Labelle, M.; Gravel, D. Unusually facile aminolysis of -
ketoesters. J. Chem. Soc., Chem. Commun., 1985, 105-106.
[35] Otera, J. Transesterification. Chem. Rev., 1993, 93, 1449-1470; and
references cited.
[36] Mottet, C.; Hamelin, O.; Garavel, G.; Depres, J-P.; Greene, A.E. A
simple and efficient preparation of propargylic -ketoesters
through transesterification. J. Org. Chem., 1999, 64, 1380-1382.
[37] Gilon, C.; Klausner, Y.; Hassner, A. A novel method for the facile
synthesis of depsipeptides. Tetrahedron Lett., 1979, 3811-3814;
and references cited.
[38] EC50 is the concentration required to achieve 50% protection of T4
lymphocyte (CEM-SS) from HIV-1 induced cytopathogenicity at 6
days post-infection, by XTT assay. Testing against HIV cytotoxic
effects towards T4 lymphocytes was carried out in a high-flux
screening programme; at National Cancer Institute, National Insti-
tutes of Health, Bethesda, Maryland, 20892, USA: Wieslow, O.S.;
Kiser R.; Fine, D.L.; Bader, J.; Shoemaker, R.H.; Boyd, M.R. New
soluble-formazan assay for HIV-1 cytopathic effects: Application
to high-flux screening of synthetic and natural products for AIDS-
antiviral activity. J. Natl. Cancer Inst., 1989, 81, 577-586.
[39] IC50 is the concentration required to inhibit HIV-1 PR activity by
50%. Testing against HIV-1 PR was carried out, courtesy of Dr. T.
Lowinger, at Bayer AG, Pharma Research, D-42096 Wuppertal,
Germany.
[40] Bergmann, M.; Zervas, L. Über ein allgemeines verfahren der
peptid-synthese. Ber. Dtsch. Chem. Ges., 1932, 65, 1192-1201.
[41] Vogel, A.I. In Vogel’s Textbook of Practical Organic Chemistry
(5th
ed); Furniss, B.S.; Hanniford, A.J.; Smith, P.W.G.; Tatchell,
A.R., Eds.; Longman Scientific and Technical, co-published with
John Wiley and Sons: New York, 1989.
[42] Thomsen, R.; Christensen, M.H. MolDock: A new technique for
high-accuracy molecular docking. J. Med. Chem., 2006, 49, 3315-
3321.
[43] Gehlhaar, D.K.; Verkhivker, G.; Rejto, P.A.; Fogel, D.B.; Fogel,
L.J.; Freer, S.T. Docking conformationally flexible small molecules
into a protein binding site through evolutionary programming. Pro-
ceedings of the Fourth International Conference on Evolutionary
Programming 1995, 615-627.

More Related Content

What's hot

Methanofuran_Biosynthesis-Jones
Methanofuran_Biosynthesis-JonesMethanofuran_Biosynthesis-Jones
Methanofuran_Biosynthesis-JonesMichael K Jones
 
T boc fmoc protocols in peptide synthesis
T boc fmoc protocols in peptide synthesisT boc fmoc protocols in peptide synthesis
T boc fmoc protocols in peptide synthesisSANTOSH KUMAR SAHOO
 
Nephar 305 physicochemical properties 16 converted
Nephar 305 physicochemical properties 16 convertedNephar 305 physicochemical properties 16 converted
Nephar 305 physicochemical properties 16 convertedRaj Nemala Raj Nemala
 
Betancourt et al 2007 SPME PHB JChrom
Betancourt et al  2007 SPME PHB JChromBetancourt et al  2007 SPME PHB JChrom
Betancourt et al 2007 SPME PHB JChromJalal Hawari
 
Solution And Solid Phase Synthesis Publication
Solution  And Solid Phase Synthesis PublicationSolution  And Solid Phase Synthesis Publication
Solution And Solid Phase Synthesis Publicationadotse
 
tboc fmoc protocol in solid phase peptide synthesis
tboc fmoc protocol in solid phase peptide synthesistboc fmoc protocol in solid phase peptide synthesis
tboc fmoc protocol in solid phase peptide synthesisSANTOSH KUMAR SAHOO
 
Liposaccharide-based nanoparticulate drug delivery system
Liposaccharide-based nanoparticulate drug delivery systemLiposaccharide-based nanoparticulate drug delivery system
Liposaccharide-based nanoparticulate drug delivery systemAdel Abdelrahim, PhD
 
Antioxidant activity of curcuma longa l., novel foodstuff
Antioxidant activity of curcuma longa l., novel foodstuffAntioxidant activity of curcuma longa l., novel foodstuff
Antioxidant activity of curcuma longa l., novel foodstuffNguyen Vinh
 
Sandrogreco Conformational Characterization Of A Camphor Based Chiral
Sandrogreco Conformational Characterization Of A Camphor Based ChiralSandrogreco Conformational Characterization Of A Camphor Based Chiral
Sandrogreco Conformational Characterization Of A Camphor Based ChiralProfª Cristiana Passinato
 
solid phase synthesis Presentation by komal
solid phase synthesis Presentation by komalsolid phase synthesis Presentation by komal
solid phase synthesis Presentation by komalKomal Rajgire
 
Hf cleavage and deprotection from resins
Hf cleavage and deprotection from resins Hf cleavage and deprotection from resins
Hf cleavage and deprotection from resins DRx Shweta Raut
 
acs%2Eorganomet%2E6b00671
acs%2Eorganomet%2E6b00671acs%2Eorganomet%2E6b00671
acs%2Eorganomet%2E6b00671Craig Young
 
plain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLET
plain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLETplain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLET
plain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLETAndrew Apals
 
Spps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesisSpps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesiskavyakaparthi1
 
Synthesis & analysis of surfactant chelating precursors on
Synthesis & analysis of surfactant chelating precursors onSynthesis & analysis of surfactant chelating precursors on
Synthesis & analysis of surfactant chelating precursors onSUMMAH aswin
 
Advanced Pharmacognosy Notes
Advanced Pharmacognosy Notes Advanced Pharmacognosy Notes
Advanced Pharmacognosy Notes Eknath Babu T.B.
 

What's hot (20)

Methanofuran_Biosynthesis-Jones
Methanofuran_Biosynthesis-JonesMethanofuran_Biosynthesis-Jones
Methanofuran_Biosynthesis-Jones
 
T boc fmoc protocols in peptide synthesis
T boc fmoc protocols in peptide synthesisT boc fmoc protocols in peptide synthesis
T boc fmoc protocols in peptide synthesis
 
Nephar 305 physicochemical properties 16 converted
Nephar 305 physicochemical properties 16 convertedNephar 305 physicochemical properties 16 converted
Nephar 305 physicochemical properties 16 converted
 
Betancourt et al 2007 SPME PHB JChrom
Betancourt et al  2007 SPME PHB JChromBetancourt et al  2007 SPME PHB JChrom
Betancourt et al 2007 SPME PHB JChrom
 
EPCI paper
EPCI paperEPCI paper
EPCI paper
 
Solution And Solid Phase Synthesis Publication
Solution  And Solid Phase Synthesis PublicationSolution  And Solid Phase Synthesis Publication
Solution And Solid Phase Synthesis Publication
 
tboc fmoc protocol in solid phase peptide synthesis
tboc fmoc protocol in solid phase peptide synthesistboc fmoc protocol in solid phase peptide synthesis
tboc fmoc protocol in solid phase peptide synthesis
 
2975 ftp
2975 ftp2975 ftp
2975 ftp
 
Liposaccharide-based nanoparticulate drug delivery system
Liposaccharide-based nanoparticulate drug delivery systemLiposaccharide-based nanoparticulate drug delivery system
Liposaccharide-based nanoparticulate drug delivery system
 
Antioxidant activity of curcuma longa l., novel foodstuff
Antioxidant activity of curcuma longa l., novel foodstuffAntioxidant activity of curcuma longa l., novel foodstuff
Antioxidant activity of curcuma longa l., novel foodstuff
 
Sandrogreco Conformational Characterization Of A Camphor Based Chiral
Sandrogreco Conformational Characterization Of A Camphor Based ChiralSandrogreco Conformational Characterization Of A Camphor Based Chiral
Sandrogreco Conformational Characterization Of A Camphor Based Chiral
 
GPR40 TL Paper
GPR40 TL PaperGPR40 TL Paper
GPR40 TL Paper
 
solid phase synthesis Presentation by komal
solid phase synthesis Presentation by komalsolid phase synthesis Presentation by komal
solid phase synthesis Presentation by komal
 
Hf cleavage and deprotection from resins
Hf cleavage and deprotection from resins Hf cleavage and deprotection from resins
Hf cleavage and deprotection from resins
 
Taiwan (2016)
Taiwan (2016)Taiwan (2016)
Taiwan (2016)
 
acs%2Eorganomet%2E6b00671
acs%2Eorganomet%2E6b00671acs%2Eorganomet%2E6b00671
acs%2Eorganomet%2E6b00671
 
plain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLET
plain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLETplain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLET
plain 4 SYNTHESIS, PURIFICATION AND STABILITY STUDY OF ISLET
 
Spps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesisSpps and side reactions in peptide synthesis
Spps and side reactions in peptide synthesis
 
Synthesis & analysis of surfactant chelating precursors on
Synthesis & analysis of surfactant chelating precursors onSynthesis & analysis of surfactant chelating precursors on
Synthesis & analysis of surfactant chelating precursors on
 
Advanced Pharmacognosy Notes
Advanced Pharmacognosy Notes Advanced Pharmacognosy Notes
Advanced Pharmacognosy Notes
 

Viewers also liked

Management of Development Team
Management of Development TeamManagement of Development Team
Management of Development TeamPiotr Trojanowski
 
Jornada de Portes Obertes a Parvulari, Primària i ESO
Jornada de Portes Obertes a Parvulari, Primària i ESOJornada de Portes Obertes a Parvulari, Primària i ESO
Jornada de Portes Obertes a Parvulari, Primària i ESOturbula
 
Practica prof campo
Practica prof campoPractica prof campo
Practica prof campoangeliquegc
 
Technology blog pw pt presentation
Technology blog pw pt presentationTechnology blog pw pt presentation
Technology blog pw pt presentationmkmcwherter
 
Sekretne składniki pomyślnych transformacji agile - 4developers2016 short
Sekretne składniki pomyślnych transformacji agile - 4developers2016 shortSekretne składniki pomyślnych transformacji agile - 4developers2016 short
Sekretne składniki pomyślnych transformacji agile - 4developers2016 shortPiotr Trojanowski
 
STaR Chart Blurb
STaR Chart BlurbSTaR Chart Blurb
STaR Chart Blurbmkmcwherter
 
Афиша губернии №1(1)
Афиша губернии №1(1)Афиша губернии №1(1)
Афиша губернии №1(1)afisha63
 
золотое рукоделие
золотое рукоделиезолотое рукоделие
золотое рукоделиеsmolinataliya
 
Shri Kshetra Shurpali Mahatme
Shri Kshetra Shurpali Mahatme Shri Kshetra Shurpali Mahatme
Shri Kshetra Shurpali Mahatme Murali Namanna
 
Музей модерна
Музей модернаМузей модерна
Музей модернаafisha63
 
Causal link between Education, Poverty and Terrorism
Causal link between Education, Poverty and TerrorismCausal link between Education, Poverty and Terrorism
Causal link between Education, Poverty and TerrorismYasin Khan
 
AFUP - Mini conférences PHP - Les LOGs
AFUP - Mini conférences PHP - Les LOGsAFUP - Mini conférences PHP - Les LOGs
AFUP - Mini conférences PHP - Les LOGsFrédéric Sagez
 
Good enough governance
Good enough governanceGood enough governance
Good enough governanceYasin Khan
 
Visual storytelling for the scientific researcher
Visual storytelling for the scientific researcherVisual storytelling for the scientific researcher
Visual storytelling for the scientific researchernigelhawtin
 
Ecommerce : Conseils et solutions avec Google AdWords
Ecommerce : Conseils et solutions avec Google AdWordsEcommerce : Conseils et solutions avec Google AdWords
Ecommerce : Conseils et solutions avec Google AdWordsDamien Marchois
 

Viewers also liked (18)

Management of Development Team
Management of Development TeamManagement of Development Team
Management of Development Team
 
Jornada de Portes Obertes a Parvulari, Primària i ESO
Jornada de Portes Obertes a Parvulari, Primària i ESOJornada de Portes Obertes a Parvulari, Primària i ESO
Jornada de Portes Obertes a Parvulari, Primària i ESO
 
Practica prof campo
Practica prof campoPractica prof campo
Practica prof campo
 
Technology blog pw pt presentation
Technology blog pw pt presentationTechnology blog pw pt presentation
Technology blog pw pt presentation
 
Sekretne składniki pomyślnych transformacji agile - 4developers2016 short
Sekretne składniki pomyślnych transformacji agile - 4developers2016 shortSekretne składniki pomyślnych transformacji agile - 4developers2016 short
Sekretne składniki pomyślnych transformacji agile - 4developers2016 short
 
STaR Chart Blurb
STaR Chart BlurbSTaR Chart Blurb
STaR Chart Blurb
 
Афиша губернии №1(1)
Афиша губернии №1(1)Афиша губернии №1(1)
Афиша губернии №1(1)
 
Kurşun kalem heykeller
Kurşun kalem heykeller Kurşun kalem heykeller
Kurşun kalem heykeller
 
золотое рукоделие
золотое рукоделиезолотое рукоделие
золотое рукоделие
 
Shri Kshetra Shurpali Mahatme
Shri Kshetra Shurpali Mahatme Shri Kshetra Shurpali Mahatme
Shri Kshetra Shurpali Mahatme
 
Музей модерна
Музей модернаМузей модерна
Музей модерна
 
Gujaratreflector.com
Gujaratreflector.comGujaratreflector.com
Gujaratreflector.com
 
Causal link between Education, Poverty and Terrorism
Causal link between Education, Poverty and TerrorismCausal link between Education, Poverty and Terrorism
Causal link between Education, Poverty and Terrorism
 
AFUP - Mini conférences PHP - Les LOGs
AFUP - Mini conférences PHP - Les LOGsAFUP - Mini conférences PHP - Les LOGs
AFUP - Mini conférences PHP - Les LOGs
 
Cyril Leveque
Cyril LevequeCyril Leveque
Cyril Leveque
 
Good enough governance
Good enough governanceGood enough governance
Good enough governance
 
Visual storytelling for the scientific researcher
Visual storytelling for the scientific researcherVisual storytelling for the scientific researcher
Visual storytelling for the scientific researcher
 
Ecommerce : Conseils et solutions avec Google AdWords
Ecommerce : Conseils et solutions avec Google AdWordsEcommerce : Conseils et solutions avec Google AdWords
Ecommerce : Conseils et solutions avec Google AdWords
 

Similar to Wardle let dds_2009

17064-9fQK1439202911-
17064-9fQK1439202911-17064-9fQK1439202911-
17064-9fQK1439202911-rajkutty1983
 
Insilico design and docking of Novel chemical compounds
Insilico design and docking of Novel chemical compoundsInsilico design and docking of Novel chemical compounds
Insilico design and docking of Novel chemical compoundsshah faisal
 
Research statement dr. khan
Research statement dr. khanResearch statement dr. khan
Research statement dr. khanAzim2015
 
Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...
Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...
Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...DrMAdamSayah
 
Facultative methylotrophic bacterium вrevibacterium
Facultative methylotrophic bacterium вrevibacteriumFacultative methylotrophic bacterium вrevibacterium
Facultative methylotrophic bacterium вrevibacteriumAlexander Decker
 
JMC 1996 39 4531LactamSulf
JMC 1996 39 4531LactamSulfJMC 1996 39 4531LactamSulf
JMC 1996 39 4531LactamSulfJ. Edward Semple
 
Biosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultativeBiosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultativeAlexander Decker
 
Biosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultativeBiosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultativeAlexander Decker
 
Test of δ- MnO2 Reactivity with Good'sBuffers
Test of δ- MnO2 Reactivity with Good'sBuffersTest of δ- MnO2 Reactivity with Good'sBuffers
Test of δ- MnO2 Reactivity with Good'sBuffersApollo Yue Nung Lin
 
A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...
A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...
A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...CrimsonpublishersMedical
 
PERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMER
PERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMERPERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMER
PERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMERRatnakaram Venkata Nadh
 
Poster PRESENTATION
Poster PRESENTATIONPoster PRESENTATION
Poster PRESENTATIONPaulami Bose
 
Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...
Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...
Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...DrMAdamSayah
 
OBC epoxidations paper - Queen Mary University LONDON UK - Thomas Follier
OBC epoxidations paper - Queen Mary University LONDON UK - Thomas FollierOBC epoxidations paper - Queen Mary University LONDON UK - Thomas Follier
OBC epoxidations paper - Queen Mary University LONDON UK - Thomas FollierThomas Follier
 
Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)
Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)
Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)DrMAdamSayah
 

Similar to Wardle let dds_2009 (20)

17064-9fQK1439202911-
17064-9fQK1439202911-17064-9fQK1439202911-
17064-9fQK1439202911-
 
OBC- 2013
OBC- 2013OBC- 2013
OBC- 2013
 
2046-1682-5-16
2046-1682-5-162046-1682-5-16
2046-1682-5-16
 
Insilico design and docking of Novel chemical compounds
Insilico design and docking of Novel chemical compoundsInsilico design and docking of Novel chemical compounds
Insilico design and docking of Novel chemical compounds
 
Research statement dr. khan
Research statement dr. khanResearch statement dr. khan
Research statement dr. khan
 
Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...
Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...
Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene ...
 
Facultative methylotrophic bacterium вrevibacterium
Facultative methylotrophic bacterium вrevibacteriumFacultative methylotrophic bacterium вrevibacterium
Facultative methylotrophic bacterium вrevibacterium
 
JMC 1996 39 4531LactamSulf
JMC 1996 39 4531LactamSulfJMC 1996 39 4531LactamSulf
JMC 1996 39 4531LactamSulf
 
Biosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultativeBiosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultative
 
Biosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultativeBiosynthesis of deuterium labeled phenylalanine. facultative
Biosynthesis of deuterium labeled phenylalanine. facultative
 
RSC
RSCRSC
RSC
 
Test of δ- MnO2 Reactivity with Good'sBuffers
Test of δ- MnO2 Reactivity with Good'sBuffersTest of δ- MnO2 Reactivity with Good'sBuffers
Test of δ- MnO2 Reactivity with Good'sBuffers
 
AJC-2015
AJC-2015AJC-2015
AJC-2015
 
A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...
A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...
A Comparison of Spectrophotometric and Oxidoreduction Potential Method for La...
 
PERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMER
PERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMERPERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMER
PERIODATE OXIDATION OF PEG–600, AN ESSENTIAL PHARMACEUTICAL POLYMER
 
JOC '96 OH-Ester HPI
JOC '96 OH-Ester HPIJOC '96 OH-Ester HPI
JOC '96 OH-Ester HPI
 
Poster PRESENTATION
Poster PRESENTATIONPoster PRESENTATION
Poster PRESENTATION
 
Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...
Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...
Pd‐PEPPSI‐IPent- Low‐Temperature Negishi Cross‐Coupling for the Preparation o...
 
OBC epoxidations paper - Queen Mary University LONDON UK - Thomas Follier
OBC epoxidations paper - Queen Mary University LONDON UK - Thomas FollierOBC epoxidations paper - Queen Mary University LONDON UK - Thomas Follier
OBC epoxidations paper - Queen Mary University LONDON UK - Thomas Follier
 
Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)
Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)
Carbon−Heteroatom Coupling Using Pd-PEPPSI Complexes (1)
 

Recently uploaded

How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesMohammad Hassany
 

Recently uploaded (20)

How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
Prelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quizPrelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quiz
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming Classes
 

Wardle let dds_2009

  • 1. Letters in Drug Design & Discovery, 2009, 6, 139-145 139 1570-1808/09 $55.00+.00 © 2009 Bentham Science Publishers Ltd. Presentation of the -Carboxamidophosphonate Arrangement in Substrate Structures Targeting HIV-1 PR N.J. Wardle*,a , H.R. Hudsonb , R.W. Matthewsb , C. Nunnb , C. Vellab and S.W.A. Bligha a Institute for Health Research and Policy; b Department of Health and Human Sciences, London Metropolitan Univer- sity, 166-220 Holloway Rd., London, N7 8DB, UK Received October 27, 2008: Revised December 05, 2008: Accepted December 15, 2008 Abstract: Novel O,O-diethyl 1-benzamido-2,2-biscarbamoylethanephosphonates were synthesised as putative substrates to HIV-1 PR, to exploit the state of activation of the phosphonate electrophilic function in -carboxamidophosphonate ar- rangements. O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2-hydroxyethyl)carbamoyl]ethanephosphonate exhibited moderate anti-HIV activity in vitro (EC50 = 53 μ ), while its depsipeptide analogue; O,O-diethyl 1-benzamido-2,2- bis[(1S)-N-(1-benzyl-2-{(2’S)-leucinyloxy}ethyl)carbamoyl]ethanephosphonate inhibited HIV-1 PR (IC50 = 31 μ ). Keywords: -carboxamidophosphonates, HIV-1 PR inhibitors, Anti-HIV agents. INTRODUCTION Human immunodeficiency virus type-1 protease (HIV-1 PR) is critical to successful completion of the viral life-cycle, initiating post-transcriptional cleavage of the viral poly- protein precursor of gag (p55) and gag-pol (p160) viral pro- teins, yielding structural proteins and enzymes essential to virion-maturation. The protease constitutes a homodimer of two 99-amino-acid-polypeptide monomers, each contribut- ing an Asp25-Thr26-Gly27 triad to the active-site, located at a cleft between the two domains as part of a four-stranded beta turn. Its pivotal role in the viral life cycle has identified HIV-1 PR as a target for therapeutic intervention, and prote- ase inhibitors (PIs) have achieved potent inhibition of viral replication in infected individuals [1-5]. PI candidates have up to this point employed non-scissile P1-P1 [6] transition- state isosteres in structures resembling natural substrates to varying degrees. These have included C2-symmetric struc- tures, exploiting the protease topology [7-15] (e.g. 1, Moz- enavir, Fig. 1) both to enhance specificity for HIV-1 PR over mammalian aspartic proteases and to optimise the P2-P2 / S2- S2 (and peripheral) interactions critical to binding potency. Structure-based approaches have achieved potent reversible, competitive inhibitory profiles in clinical drug combination (HAART) regimens [16]. Meanwhile, mechanism-based approaches employing affinity labels have yielded irreversi- ble, non-competitive inhibitors (e.g. 2, Fig. 1). While corre- sponding PI candidates have yet to find clinical application [17-22], the latter approach has the potential to provide po- tent inhibition at lower concentrations than are required with non-competitive inhibitors (thereby reducing toxicity). Various hydrolytic studies have characterised an acute activation of the -carboxyl/carboxamidophosphonate motif, and its phosphinate analogue, to nucleophilic displacement at phosphorus under acidic conditions, either via hydrogen- bonded [23] or mixed cyclic carboxyl/carboxamidyl- *Address correspondence to this author at the Institute for Health Research and Policy, Tower Building, London Metropolitan University, 166-220 Holloway Rd., London, N7 8DB, UK; Tel: +44 207 133 2140; Fax: +44 207 133 2096; E-mail: n.wardle@londonmet.ac.uk phosphonyl anhydride [24-28] intermediates (Scheme 1). Analogous activation within an enzyme-inhibitor (EI) com- plex of HIV-1 PR could offer scope for interaction with various enzymatic residues, subject to the positioning of the inhibitor’s “warhead” [29] function. Potential interactions would include covalent adduct formation (e.g. with Thr 26/26’ or Thr31/31’ residues), or alternatively sequestration of enzymatic water (e.g. the water molecule hydrogen- bonded to Ile50/50’ binding-flap residues) in hydrolysis. The water molecule specified in parenthesis is critical to ES bind- ing interactions [3,30], and its functional replacement has previously featured as a target for inhibitor design [11-16] in order to exploit the entropic gain arising from liberation of the protein-bound water to bulk solvent [31]. In the context of the titled structures, hydrolytic sequestration of this water molecule could release the alcohol by-product of displace- ment to bulk solvent, while retaining hydrogen-bonding in- teractions with Ile50/50’ residues through the modified phosphonate function. Therefore, the titled compounds were developed to present the above motif in pseudo-C2- symmetric, peptidomimetic structures commensurate with the binding criteria of HIV-1 PR. 1 Mozenavir N N O HO OH N H N N H O O S O N S O O O O 2 H2N NH2 Fig. (1). Examples of reversible (1) and irreversible (2) inhibitors of HIV-1 PR.
  • 2. 140 Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 Wardle et al. RESULTS AND DISCUSSION Modelling “Molegro” virtual docking experiments indicated flexi- ble docking of ligand 3 (Scheme 2) within the negatively charged active-site binding pocket of the protease dimer, and hydrogen-bonding interactions were exhibited in top-ranked poses, between components of the N-(1-phenyl-2- hydroxyethyl)carbamoyl functions of 3 and the Gly27 and Gly48 enzymatic residues respectively (of 1.7Å and 2.3Å distance in the lowest energy conformation, Fig. 2). The lowest energy conformation also exhibits one - biscarbamoyl oxo-function of 3 proximal (2.1Å) to the ac- tive-site Asp25 carboxyl, and suggests scope for interaction between the ligand’s phosphonate function and the Ile50/50 - bound structural water molecule described above. With re- spect to enzymatic Ile50/50 N-atoms, the ligand P=O phos- phorus atom is placed at 6.3Å and 6.0Å distances respec- tively and the corresponding oxygen atom at 5.1Å and 4.8Å distances. Chemistry The synthetic route followed for the titled O,O-diethyl 1- benzamido-2,2-biscarbamoyl-ethanephosphonates is illus- trated in Scheme 2. AdN-E reaction between diethyl ethoxymethylenemalonate (4) and benzamide at 180-200o C over 6 h gave diethyl benzamidomethylenemalonate (5, 40%). Thereafter, a base-catalysed Michael addition of di- ethyl phosphite across the olefinic function therein [32,33] generated O,O-diethyl benzamido[diethoxyphosphinyl] methyl malonate (6, 82%) from which the biscarbamoyl structure would be constructed by aminolysis. The state of activation towards nucleophilic substitution recorded in eno- lizable -dicarbonyl ester systems [34-36] led to an anticipa- tion of desired chemoselectivity of substitution, despite the presence in malonate 6 of two functions (i.e. carboxylate and phosphonate) potentially reactive to the same reagents and catalysts. Accordingly, desired bis[N-(1-phenyl-2-hydroxy- ethyl)carbamoyl] derivative 3 was generated in a methanolic medium in 18% yield from 6 using a minor excess of (2S)- phenylalaninol at maximum practicable concentration and mildly elevated temperature (45-55o C, 14 days). Use of simi- lar conditions in preliminary procedures involving benzy- lamine and straight-chain alkanolamine reagents abnegated P O O RO X intramolecular H-bonded intermediates mixed cyclic carboxyl/ carboxamidyl-phosphonyl anhydride X = O, N R''R''' P O O O RO O H or P O O O RO H OR R P R' O RO RO O R = alkyl R' = OH, NR''R''' reactive intermediate P R' O HO HO O Scheme 1. Accelerated hydrolysis of phosphonate functions via active intermediates. Fig. (2). Lowest docked energy conformation of ligand 3 showing hydrogen bonding interactions.
  • 3. Presentation of the -Carboxamidophosphonate Arrangement Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 141 chemoselectivity, necessitating procedures conducted at room temperature to generate the corresponding bis-N- carbamoyl derivatives. Significant excess of amine reagent invariably resulted in concomitant mono-dealkylation of the phosphonate function, while use of organonitrogen nucleo- philic/base catalysts (i.e. aniline, pyridine, imidazole etc.) also diminished chemoselectivity unacceptably. In addition to their function as putative binding determi- nants, the hydroxyl functions of 3 permit modification of lipophilicity/water-solubility characteristics via derivatiza- tion to depsipeptides - an established method of enhancing drug bioavailability. DCC/DMAP-mediated coupling [37] furnished enantiopure Cbz-leucinyl derivative 7 (66%), which was deprotected by catalytic hydrogenolysis at atmos- pheric pressure over Pd/C (5% w/w, CAUTION) and iso- lated as dihydrochloride salt 8 of the enantiopure depsipep- tide (72%). 4 R = EtO 5 R = BzNH i 5, ii 3 R' = OH 7 R' = O-(2S)-Leu-Cbz 8 R' = O-(2S)-Leu-NH2.HCl iv v iii 6 EtO OEt O O R OEtEtO OO NH(EtO)2P O O R' H N H N R' O O (EtO)2P NH O O Scheme 2. (i) BzNH2, ; (ii) HP(O)(OEt)2, NaOEt (cat), ; (iii) (S)- phenylalaninol (2.1 eqv.), 45-55o C; (iv) Cbz-leu-OH, DCC, DMAP (cat.); (v) Pd/C (5%), H2, then dry HCl/Et2O. Biological Activity Compounds were tested for in vitro anti-HIV activity at the National Institutes of Health, USA (NIH) against the T- cell line adapted isolate HIV-1LAI/3B (3B) in CEM-SS cells using a standard XTT assay [38]. Compound 3 was found to be moderately active (EC50 = 53 μM), while attempts to en- hance cellular uptake through development of depsipeptide structures resulted in a loss of in vitro activity in leucinyl derivatives 7 and 8 (EC50 > 200μM). However, in HIV-1 PR binding studies, the binding of 8 proved superior to that of 3 (IC50 = 31 μM and >50 μM respectively) [39]. CONCLUSIONS In summary, a putative ligand to HIV-1 PR, i.e. 3, consti- tuting a -carboxamidophosphonate arrangement, has been developed; exhibiting moderate anti-HIV activity in vitro. While the enhanced HIV-1 PR binding of depsipeptide 8 compared with that of 3 is explicable in terms of alternative binding modes and participation of the leucinyl function in EI interactions, the lack of anti-HIV activity of 8 (and 7) in vitro compared with 3 has yet to be explained, although a correlation with the relative efficacies of intracellular trans- port of these compounds may be possible. EXPERIMENTAL SECTION General NMR spectra were recorded at ambient temperature (un- less otherwise stated), on a Bruker AM-250 (1 H, 1 H-1 H COSY, 250.13 MHz; 13 C, 135-DEPT, 62.90 MHz; 31 P, 101.26 MHz) or Bruker Avance-500 (1 H, 1 H-1 H COSY, 500.13 MHz; 13 C, 135-DEPT, 125.77 MHz; 31 P, 202.45 MHz) spectrometer in pulse Fourier transform (pFt) mode. All 13 C and 31 P NMR spectra are 1 H-broad-band decoupled. 1 H and 13 C NMR spectra were referenced internally to Me4Si. Aqueous phosphoric acid (85% H3PO4) was used as the external reference for 31 P NMR spectra. Infrared spectra were recorded on a Bruker Vector 22 FT-IR or Nicolet IR- 100 FT-IR spectrophotometer, with samples prepared as 16mm diameter KBr discs. Mass spectrometry was per- formed either using a Kratos Profile HV3 mass spectrometer in “Liquid Secondary Ionization Mass Spectrometry” mode (employing glycerol as a matrix), or a Finnigan 710C spec- trometer with an electrospray source in positive ion mode. Melting points were obtained on an Electrothermal Eng. Ltd. digital melting-point apparatus, and are uncorrected. A Carlo Erba 1108 Elemental Analyser was used for C, H and N mi- croanalyses. TLC was performed on precoated silica plates (Whatman Al Sil G/UV, 250 μm layer) using CH2Cl2/MeOH, 50:3 (v/v) as solvent eluent; denoted “sys- tem A” in the experimental section. Reagents were used as purchased. (2S)-Cbz-Leucine was prepared according to the methodology of Zervas et al. [40]. Drying (and storage) of solvents when necessary were car- ried out according to established methods [41]. Synthesis Diethyl Benzamidomethylenemalonate (5). A suspen- sion of benzamide (78.74 g, 650.0 mmol) in diethyl ethoxymethylenemalonate 4 (140.55 g, 650.0 mmol) was heated at 180-200o C in a distillation apparatus fitted with a Dean-Stark trap, until one equivalent of ethanol had been collected (6 h). When cool, the oily mixture was washed with petroleum ether (3x150 cm3 ), triturated in petroleum ether (300 cm3 ) and left to crystallize in the ether over sev- eral days. The solid formed was isolated, and recrystalliza- tion from 99IMS/petroleum ether (1:1) solution yielded 5 as a waxy, yellow solid (76.23 g, 40%). Rf 0.87 (system A, u.v. abs.), mp 42-45o C; IR: 3446, 1724, 1706, 1666, 1604, 1453, 1377, 1267, 1246, 1216, 1077, 1068, 1059; H(CDCl3): 1.35, 1.40 [6H, 2x t, J 7.1, 2x CH3]; 4.28, 4.36 [4H, 2x q, J 7.1, 2x CH2]; 7.40-7.68 [3H, m’s, m,p-Ar-H]; 7.975, 7.98 [2H, 2x d,
  • 4. 142 Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 Wardle et al. J 7.3, 7.0 resp., o-Ar-H]; 8.78 [1H, d, J 11.8, C=CH]; 12.02 [1H, br.d., J 11.8, NH]; C(CDCl3): 14.17, 14.27 [2x CH3]; 60.88, 61.41 [2x CH2]; 102.74 [HC=C]; 127.54, 128.00, 128.60, 129.12, 131.46 (ipso), 133.61 [Ar-C]; 146.94 [HC=C]; 164.26, 164.47, 167.98 [C=O’s]; MS (LSIMS): 292 (81%, [MH]+ ). Anal. Calcd for C15H17NO5: C, 61.85; H, 5.88; N, 4.81%. Found: C, 62.07; H, 6.00; N, 4.81%. Diethyl Benzamido[diethoxyphosphinyl]methyl Malo- nate (6). A vigorously stirred reaction mixture of 5 (58.50 g, 200.0 mmol) in freshly distilled diethyl phosphite (30.38g, 220.0 mmol) was heated to 65o C, at which time heating was stopped as ethanolic sodium ethoxide solution was added dropwise (~ 1 M, 1 cm3 ). An exothermic reaction was ob- served immediately, the reaction temperature rising to 100o C, and the temperature was maintained at 90-95o C for 2.5 h after the exothermic reaction had subsided. Diethyl ether (20 cm3 ) was added to the cooled mixture and the re- sulting solution was immediately filtered. Material crystal- lized from the filtrate over several days was isolated in two crops and washed with diethyl ether (20 cm3 , dropwise) to leave 6 as a crystalline white solid (70.38 g, 82%). Rf 0.52 (system A, I2 vis.), mp 86-90o C; IR: 3274, 1700, 1671, 1545, 1539, 1321, 1311, 1245, 1227, 1047, 1015, 983, 966; H(CDCl3): 1.21, 1.29, 1.34 [12H, 3x t, J 7.1, 7.1, 7.2 resp., 4x CH3]; 4.02 [1H, dd, J1 5.3, J2 3.1, C H]; 4.08-4.39 [8H, m’s, 4x CH2]; 5.39 [1H, ddd, J1 17.9, J2 9.8, J3 3.1, C H]; 7.40-7.53 [3H, m’s, m,p-Ar-H]; 7.81, 7.82 [2H, 2x d, J 6.8, 6.7 resp., o-Ar-H]; 7.89 [1H, br.d, J ~9.8, NH]; C(CDCl3): 13.93, 13.97 [2x C(O)OCH2CH3]; 16.33, 16.39 [2x d, J 5.7, 5.5 resp., P(OCH2CH3)2]; 45.76 [d, J 161.8, C ]; 50.59 [d, J 5.1, C ]; 62.12, 62.45 [2x C(O)OCH2]; 63.16, 63.33 [2x d, J 6.6, 6.9 resp., P(OCH2CH3)2]; 127.14, 127.81, 128.59, 128.68, 131.86 [o,m,p-Ar-C], 133.73 [ipso-Ar-C]; 166.45, 166.69, 168.62 [3x d, J 3.8, 18.1, 2.8 resp., C=O’s]; P(CDCl3): 21.06; MS (LSIMS): 430 (100%, [MH]+ ). Anal. Calcd for C19H28NO8P: C, 53.15; H, 6.57; N, 3.26%. Found: C, 53.46; H, 6.67; N, 3.17%. O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2-hyd- roxyethyl)carbamoyl]ethanephosphonate (3). A methanolic solution (10 cm3 ) of malonate 6 (6.87 g, 16.0 mmol) and (2S)-2-amino-3-phenyl-1-propanol (5.41 g, 35.8 mmol, ~ 2.1 equiv.) was stirred at 45-55o C for 14 days (monitored by TLC; solvent system A) under anhydrous conditions. The reaction mixture was evaporated in vacuo, redissolved in ethyl acetate (200 cm3 ), and the solution was washed with deionised water (2x100 cm3 ), 0.2N HCl solution (2x100 cm3 ), sat’d NaHCO3 solution (2x100 cm3 ) and sat’d brine (2x100 cm3 ) respectively. The organic phase was dried over MgSO4 and evaporated in vacuo. Column chromatography over silica (CH2Cl2/MeOH; 89:11 v/v) yielded a clear oil from which a white solid was crystallized in methanol (5 cm3 ). Washing of the isolated solid with acetone and diethyl ether yielded 3 as a white powder (1.87 g, 18%). Rf 0.33 (system A, u.v. abs.), mp 186-187o C; IR: 3419, 3305, 1700, 1692, 1672, 1652, 1539, 1329, 1252, 1232, 1052, 1032, 971; H(DMSO-d6): 1.15, 1.21 [6H, 2x t, J 6.9, 7.0 resp., 2x CH3)]; 2.58-2.82 [4H, m’s, 2x CH2Ph]; 3.08-3.38 [4H, 2x m, 2x CH2OH]; 3.78 [1H, dd, J1J2 7.7, C H]; 3.72-4.07 [6H, m’s, P(OCH2CH3)2 and 2x NCHBn]; 4.78, 4.81 [2H, 2x t, J 5.3, 5.6 resp., 2x OH]; 5.08 [1H, ddd, J1 14.7, J2 8.2, J3 7.7, C H]; 7.13-7.29 [10H, m’s, Ar-H {Bn}]; 7.43-7.58 [3H, m’s, m,p-Ar-H {Bz}]; 7.73 [1H, d, J 8.2, NHCH]; 7.75 [2H, d, J 8.1, o-Ar-H {Bz}]; 8.00 [1H, d, J 8.2, NHCH]; 8.68 [1H, d, J 8.2, BzNH]; C(DMSO-d6): 16.14 [2x d, J 5.9, 2x CH3]; 35.89, 36.12 [2x CH2Ph]; 46.39 [d, J 158.5, C ]; 51.46 [d, J 5.6, C ]; 52.51, 52.64 [2x CHBn]; 61.03, 61.43 [2x HOCH2]; 62.04, 62.31 [2x d, J 6.6, 6.9 resp., P(OCH2CH3)2]; 125.91, 127.00, 128.05, 128.10, 128.31, 128.96, 129.10, 131.30 [o,m,p-Ar-C], 134.08 [ipso-Ar-C {Bz}]; 138.59, 138.63 [2x ipso-Ar-C {Bn}]; 165.59, 165.68, 167.12 [3x d, J 5.5, 11.3, 10.2 resp., C=O’s]; P(DMSO-d6): 23.59; MS (LSIMS): 641 (100%, [MH]+ ). Anal. Calcd for C33H42N3O8P: C, 61.96; H, 6.62; N, 6.57%. Found: C, 61.96; H, 6.73; N, 6.46%. O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2- {(2’S)-N-[benzyloxycarbonyl]leucinyloxy}ethyl) carbamoyl]- ethanephosphonate (7). A dichloromethane solution (25 cm3 ) containing DCC (0.70 g, 3.4 mmol), (2S)-Cbz-leucine (0.83 g, 3.1 mmol), phosphonate 6 (0.83 g, 1.3 mmol) and DMAP (0.06 g, 0.5 mmol) was stirred at 0o C for 30 min, and at rt for 72 h thereafter, with moisture excluded. The mixture was filtered, the isolated solid was washed with dichloro- methane (3x20 cm3 ), and the combined filtrate and washings were evaporated in vacuo (40o C). An ethyl acetate solution of the residue (250 cm3 , filtered after 3 days) was washed with ice-cold 1N HCl solution (2x250 cm3 ), sat’d NaHCO3 solution (2x250 cm3 ) and sat’d brine (2x250 cm3 ) respec- tively, dried over MgSO4, and evaporated in vacuo to leave a semi-solid residue. Column chromatography over silica (CH2Cl2/MeOH; 91:9 v/v) yielded 7 as a clear glass (0.97 g, 66%). Rf 0.40 (system A, u.v. abs.), softening pt 56-59o C; IR: 3413, 3291, 2957, 1749, 1724, 1676, 1532, 1243, 1048, 1026, 978; H(DMSO-d6): 0.88, 0.90 [12H, 2x d, J 6.2, 6.3 resp., 4x CH3 {Leu}]; 1.15, 1.20 [6H, 2x t, J 7.0, P(OCH2CH3)2]; 1.43-1.82 [6H, m’s, 2x CHCH2Me2]; 2.55- 2.74 [4H, m’s, 2x CH2Ph {Bn}]; 3.77-3.89 [4H, 2x m, 2x CH2OLeu]; 3.80-3.90 [1H, m, C H]; 3.89-4.11 [4H, m, P(OCH2CH3)2]; 4.08-4.29 [4H, m, 2x NCHBn and 2x NCH {Leu}]; 5.03-5.14 [1H, m, C H]; 5.03, 5.04 [4H, 2x s, 2x CH2 {Cbz}]; 7.15-7.35 [20H, m’s, Ar-H {Cbz, Bn}]; 7.41- 7.54 [3H, m, m,p-Ar-H {Bz}]; 7.74 [2H, d, J 7.3, o-Ar-H {Bz}]; 7.79, 7.97, 8.12 [4H, 3x d, J 8.3, 7.8, 7.8 resp., 4x NHCH]; 8.72 [1H, d, J 9.1, BzNH]; C(DMSO-d6): 16.10 [d, J 5.2, P(OCH2CH3)2]; 20.97, 22.63 [4x CH3 {Leu}]; 24.15 [2x CHMe2]; 35.90, 36.00 [2x CH2 {Leu}]; 39.33 [2x CH2 {Bn}]; 46.44 [d, J 175.5, C ]; 49.04 [2x NCHLeu]; 51.37 [C ]; 52.18 [2x NCHBn]; 61.97, 62.24 [2x d, J 6.7, P(OCH2CH3)2]; 64.05, 64.37 [2x CH2OLeu]; 65.43 [CH2 {Cbz}]; 126.17, 126.91, 127.56, 127.69, 128.19, 128.33, 128.83, 128.95 [o,m,p-Ar-C], 133.90 [ipso-Ar-C {Bz}]; 136.72, 136.74, 137.46 [ipso-Ar-C {Cbz, Bn}]; 156.03, 156.06 [C=O’s {Cbz}]; 165.65, 165.71, 165.87, 166.98, 167.13 [C=O’s, {Cbm, Bz}]; 172.31, 172.41 [C=O’s, {es- ter}]; P(DMSO-d6): 23.31; MS (LSIMS): 1133 (63%, [MH]+ ). Anal. Calcd for C61H74N5O14P: C, 64.71; H, 6.59; N, 6.19%. Found: C, 64.94; H, 6.65; N, 6.09%. O,O-Diethyl 1-benzamido-2,2-bis[(1S)-N-(1-benzyl-2- {(2’S)-leucinyloxy}ethyl)carbamoyl]-ethanephosphonate Di-hydrochloride Salt (8). Pd/C (5% Pd w/w, 0.51 g, CAU- TION; pyrophoric in air) was added to a suspension of phosphonate ester 7 (0.29 g, 0.25 mmol) in absolute ethanol (50 cm3 ) at 0o C under an atmosphere of N2. The mixture was stirred under N2 for 10 min and under a stream of dry H2 gas
  • 5. Presentation of the -Carboxamidophosphonate Arrangement Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 143 for 3 h thereafter (1.5 h at rt, and 1.5 h at 50o C), then filtered through a column of Celite 521 filter agent under N2. The filtrate was evaporated in vacuo, redissolved in diethyl ether (50 cm3 , seeded with methanol), and bubbled with dry HCl gas for 30 min at 0o C. Evaporation in vacuo, and trituration of the residue in petroleum ether afforded 8 as a cream-white powder (0.17 g, 72%), mp 134-136o C; IR: 3431, 3300, 2960, 1752, 1686, 1533, 1221, 1048, 1026, 977; H(DMSO-d6): 0.88, 0.90 [12H, 2x d, J 5.9, 4x CH3 {Leu}]; 1.12, 1.18 [6H, 2x t, J 7.1, 7.2, P(OCH2CH3)2]; 1.45-1.93 [6H, m’s, 2x CH2CHMe2]; 2.70-3.00 [4H, m’s, 2x CH2Ph]; 3.70-4.38 [13H, m’s, P(OCH2CH3)2, C H, 2x NCHBn, 2x NCH {Leu} and 2x CH2OLeu]; 5.11 [1H, m, C H]; 7.18-7.40 [10H, m, Ar-H {Bn}]; 7.43-7.54 [3H, m, m,p-Ar-H {Bz}]; 7.82 [2H, d, J 7.3, o-Ar-H {Bz}]; 8.20-9.05 [~9H, m’s, 7x NH and 2x HCl]; C(DMSO-d6): 16.17 [d, J 2.7, P(OCH2CH3)2]; 21.89, 21.97 [4x CH3 {Leu}]; 23.66 [2x CHMe2]; 35.83, 36.11 [2x CH2 {Leu}]; 38.71 [2x CH2 {Bn}]; 45.96 [d, J 157.2, C ]; 49.25, 49.88 [4x NCH]; 50.67 [C ]; 62.00, 62.24 [2x d, J 7.0, 6.6 resp., P(OCH2CH3)2]; 65.71, 65.88 [2x CH2OLeu]; 126.22, 127.11, 128.22, 128.92, 128.99, 131.27 [o,m,p-Ar- C], 133.95 [ipso-Ar-C {Bz}]; 137.85, 137.94 [ipso-Ar-C {Bn}]; 163.21, 165.46, 165.96, 166.07, 167.02, 169.09 [C=O’s]; P(DMSO-d6): 23.29, 24.87 (95:5 resp., rt) 22.70 (100o C); MS (Es-MS): 866 (100%, [MH]+ {free amine}); MS (LSIMS): 866 (32%, [MH]+ {free amine}). Anal. Calcd for C45H64N5O10P.2HCl: C, 57.56; H, 6.87; N, 7.46%. Found: C, 57.41; H, 6.88; N, 7.58%. Computational Details The X-ray crystal structure of HIV-1 protease (PDB code 1HSG) was used as a model for the HIV-1 protease. The 3-D coordinates for the structure of ligand 3, including hydrogen atoms, were generated using Chem3D Ultra version 10.0 (ChemOffice 2006, CambridgeSoft Corporation) and energy minimised. Modelling of the ligand into the active site of HIV-1 protease was carried out using the Molegro virtual docker which utilises the MolDock algorithm [42]; a hybrid search algorithm called “guided differential evolution” which combines the differential evolution optimisation tech- nique with a cavity prediction algorithm. The docking scor- ing function of MolDock is based upon a piecewise linear potential [43], and the docking procedure was randomized with a minimum of 10 runs and 5000 iterations. The best five poses (ligand orientation) generated were recalculated and re-ranked by analyzing the energy scores, binding affinities, and ligand-residue (H-bond) interactions, and the top-ranked pose was visualized using the Molegro virtual docker visu- alization software. Anti-HIV Activity: XTT Assay The XTT assay was performed at NIH as described [38]. Briefly, stock solutions of the compounds were prepared in DMSO and serial half log10 dilutions (10-3 M to 10-7 M) added to 3B-infected CEM-SS cells. After 6 days, the tetrazolium salt XTT and phenazine methosulfate were added to the cells, and the assay incubated to allow formazin colour de- velopment by metabolically active viable cells. Colour de- velopment was analysed spectrophotometrically to quantitate formazin production in individual wells. Compound-treated, virus-infected wells were compared both with untreated, virus-infected wells and with controls. Uninfected, treated cells served as a control for compound-induced cytotoxicity while AZT-treated, infected cells served as a positive control for protection from 3B-induced cell death. The concentration protecting 50% of cells (EC50) from 3B-induced cell death was calculated. ACKNOWLEDGEMENTS We thank Mr. J. Crowder for running NMR spectra, Mr. W. Dissanayake for running mass spectra, and Mr. S. Boyer for running C, H, N microanalysis. We also thank the Thrombosis Research Institute for the mass spectrometry performed on compound 8. Dr T. Lowinger of Bayer AG, Wuppertal, Germany is thanked for bioevaluation against HIV-1 PR; and NIH, Bethesda, USA, is also thanked for evaluating anti-HIV activity. ABBREVIATIONS abs = absorption AdN-E = addition-elimination Asp = aspartic acid Bn = benzyl br = broad Bz = benzoyl Cbz = carbobenzyloxy Cbm = carbamoyl COSY = correlated spectroscopy DCC = N,N-dicyclohexylcarbodiimide DEPT = distortionless enhancement by polarisation transfer DMAP = 4-dimethylaminopyridine DMSO = dimethyl sulfoxide EI = enzyme-inhibitor complex or interaction ES = enzyme-substrate complex or interaction Es-MS = electrospray mass spectrometry Gly = glycine HAART = “highly active anti-retroviral therapy;” imp = impurity 99IMS = industrial methylated spirits (denatured etha- nol) Leu = leucine LSIMS = liquid secondary ionization mass spectrome- try resp = respectively rt = room temperature sat’d = saturated Thr = threonine vis = visualization
  • 6. 144 Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 Wardle et al. XTT- = 2,3-bis[2-methoxy-4-nitro-5-sulfo-phenyl]-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide o-, m-, p- = ipso- are used according to the standard convention for aromatic substituents C and C = denote carbons of the central ethane motif at positions and respectively to phospho- rus. REFERENCES AND NOTES [1] Deeks, S.G.; Smith, M.; Holodniy, M.; Kahn, J.O. HIV-1 Protease Inhibitors. A review for clinicians. J. Am. Med. Assoc., 1997, 277, 145-153. [2] Dougherty, W.G.; Semler, B.L. Expression of virus-encoded prote- inases: Functional and structural similarities with cellular enzymes. Microbiol. Rev., 1993, 57, 781-822. [3] Wlodawer, A.; Erickson, J.W. Structure-based inhibitors of HIV-1 Protease. Annu. Rev. Biochem., 1993, 62, 543-585. [4] Leung, D.; Abbenante, G.; Fairlie D.P. Protease Inhibitors: Current status and future prospects. J. Med. Chem., 2000, 43, 305-341. [5] De Clercq, E. New anti-HIV agents and targets. Med. Res. Rev., 2002, 22, 531-565. [6] For oligopeptide residue notation see; Schechter, I.; Berger, A. On the size of the active site in proteases. Biochem. Biophys. Res. Commun., 1967, 27, 157-162. [7] Kempf, D.J.; Codacovi, L.; Wang, X.C.; Kohlbrenner, W.E.; Wideburg, N.E.; Saldivar, A.; Vasavanonda, S.; Marsh, K.C.; Bryant, P.; Sham, H.L.; Green, B.E.; Betebenner, D.A; Erickson, J.; Norbeck, D.W. Symmetry-based inhibitors of HIV Protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3- hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J.Med. Chem., 1993, 36, 320-330. [8] Alterman, M.; Björsne, M.; Mühlman, A.; Classon, B.; Kvarn- ström, I.; Danielson, H.; Markgren, P-O.; Nillroth, U.; Unge, T.; Hallberg, A.; Samuelsson, B. Design and synthesis of new potent C2-symmetric HIV-1 Protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. J. Med. Chem., 1998, 41, 3782-3792. [9] For review of phosphinic acid-based C2-symmetric inhibitors see Section 5.1 of; Wardle, N.J.; Bligh, S.W.A.; Hudson, H.R. Organo- phosphorus Chemistry: Therapeutic intervention in mechanisms of viral and cellular replication. Curr. Org. Chem., 2005, 9, 1803- 1828. [10] DMP-450 (Mozenavir) - ; Hodge, C.N.; Aldrich, P.E.; Bacheler, L.T.; Chang, C-H.; Eyermann, C.J.; Garber, S.; Grubb, M.; Jack- son, D.A.; Jadhav, P.K.; Korant, B.; Lam, P.Y.S.; Maurin, M.B.; Meek, J.L.; Otto, M.J.; Rayner, M.M.; Reid, C.; Sharpe, T.R.; Shum, L.; Winslow, D.L.; Erickson-Viitanen, S. Improved cyclic urea inhibitors of the HIV-1 Protease: Synthesis, potency, resis- tance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem. Biol., 1996, 3, 301-314. [11] DMP-323 - ; Lam, P.Y.S.; Ru, Y.; Jadhav, P.K.; Aldrich, P.E.; DeLucca, G.V.; Eyermann, C.J.; Chang, C-H.; Emmett, G.; Holler, E.R.; Daneker, W.F.; Li, L.; Confalone, P.N.; McHugh, R.J.; Han, Q.; Li, R.; Markwalder, J.A.; Steitz, S.P.; Sharpe, T.R.; Bacheler, L.T.; Rayner, M.M.; Klabe, R.M.; Shum, L.; Winslow, D.L.; Korn- hauser, D.M.; Jackson, D.A.; Erickson-Viitanen, S.; Hodge, C.N. Cyclic HIV Protease Inhibitors: Synthesis, conformational analysis, P2/P2’structure-activity relationship, and molecular recognition of cyclic ureas. J. Med. Chem., 1996, 39, 3514-3525. [12] Nugiel, D.A.; Jacobs, K.; Worley, T.; Patel, M.; Kaltenbach III, R.F.; Meyer, D.T.; Jadhav, P.K.; De Lucca, G.V.; Smyser, T.E.; Klabe, R.M.; Bacheler, L.T.; Rayner, M.M.; Seitz, S.P. Preparation and structure-activity relationship of novel P1/P1’-substituted cy- clic urea-based human immunodeficiency virus type-1 protease in- hibitors. J. Med. Chem., 1996, 39, 2156-2169. [13] Jadhav, P.K.; Ala, P.; Woerner, F.J.; Chang, C-H.; Garber, S.S.; Anton, E.D.; Bacheler, L.T. Cyclic urea amides: HIV-1 Protease with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem., 1997, 40, 181- 191. [14] Han, Q.; Chang, C-H.; Li, R.; Ru, Y.; Jadhav, P.K.; Lam, P.Y.S. Cyclic HIV-Protease Inhibitors: Design and synthesis of orally bioavailable pyrazole P2/P2’cyclic ureas with improved potency. J. Med. Chem., 1998, 41, 2019-2028. [15] Ax, A.; Schaal, W.; Vrang, L.; Samuelsson, B.; Hallberg, A.; Kar- lén, A. Cyclic sulfamide HIV-1 Protease inhibitors with sidechains spanning from P2/P2’ to P1/P1’. Bioorg. Med. Chem., 2005, 13, 755-764; and references cited. [16] De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Virol., 2004, 30, 115-133. [17] Meek, T.D.; Dayton, B.D.; Metcalf, B.W.; Dreyer, G.B.; Strickler, J.E.; Gorniak, J.G.; Rosenberg, M.; Moore, M.L.; Magaard, V.W.; DeBouck, C. Human immunodeficiency virus 1 protease expressed in Escherichia Coli behaves as a dimeric aspartic protease. Proc. Natl. Acad. Sci. USA, 1989, 86, 1841-1845. [18] Park, C.; Koh, J.S.; Son, Y.C.; Choi, H-il.; Lee, C.S.; Choy, N.; Moon, K.Y.; Jung, W.H.; Kim, S.C.; Yoon, H. Rational design of irreversible psuedo-C2-symmetric HIV-1 Protease inhibitors. Bioorg. Med. Chem. Lett., 1995, 5, 1843-1848. [19] Yu, Z.; Caldera, P.; McPhee, F.; De Voss, J.J.; Jones, P.R.; Burlingame, A.L.; Kuntz, I.D.; Craik, C.S.; Ortiz de Montellano, P.R. Irreversible inhibition of the HIV-1 Protease: Targeting alky- lating agents to the catalytic aspartate groups. J. Am. Chem. Soc., 1996, 118, 5846-5856. [20] Choy, N.; Choi, H-il.; Jung, W.H.; Kim, C.R.; Yoon, H.; Kim, S.C.; Lee, T.G.; Koh, J.S. Synthesis of irreversible HIV-1 Protease inhibitors containing sulfonamide and sulfone as amide bond isos- teres. Bioorg. Med. Chem. Lett., 1997, 7, 2635-2638. [21] De Voss, J.J.; Sui, Z.; DeCamp, D.L.; Salto, R.; Babé, L.M.; Craik, C.S.; Ortiz de Montellano, P.R. Haloperidol-based irreversible in- hibitors of the HIV-1 and HIV-2 Proteases. J. Med. Chem., 1994, 37, 665-673. [22] Zutshi, R.; Chmielewski, J. Targeting the dimerization interface for irreversible inhibition of HIV-1 Protease. Bioorg. Med. Chem. Lett., 2000, 10, 1901-1903. [23] Gordon, M.; Notaro, V.A.; Griffin, C.E. Phosphonic acids and esters. VII. Intramolecular electrophilic catalysis of phosphonate ester hydrolysis by neighboring carboxyl. J. Am. Chem. Soc., 1964, 86, 1898-1899. [24] Jacobsen, N.E.; Bartlett, P.A. Cyclic phosphonic-carboxylic imides and anhydrides as reactive intermediates. 1. Rearrangement and solvolysis of N-[amino(methyl)phosphinyl]-L-phenylalanine de- rivatives. J. Am. Chem. Soc., 1983, 105, 1613-1619. [25] Jacobsen, N.E.; Bartlett, P.A. Cyclic phosphonic-carboxylic imides and anhydrides as reactive intermediates. 2. Solvolysis of N- [hydroxy(methyl)phosphinothioyl]-L-phenylalanine. J. Am. Chem. Soc., 1983, 105, 1619-1626. [26] Georgiadis, D.; Dive, V.; Yiotakis, A. Synthesis and comparative study on the reactivity of peptidyl-type phosphinic esters: In- tramolecular effects in the alkaline and acidic cleavage of methyl -carboxyphosphinates. J. Org. Chem., 2001, 66, 6604-6610. [27] Reiter, L.A.; Jones, B.P. Amide-assisted hydrolysis of - carboxamido-substituted phosphinic acid esters. J. Org. Chem., 1997, 62, 2808-2812. [28] Kluger, R.; Chan, J.L.W. Amide-phosphate interactions: Acid catalysis in amide-assisted hydrolysis of phosphonate esters. J. Am. Chem. Soc., 1976, 98, 4913-4917; and references cited. [29] Walsh, C. Suicide Substrates: Mechanism-based enzyme inactiva- tors. Tetrahedron, 1982, 38, 871-909. [30] Okimoto, N.; Tsukui, T.; Kitayama, K.; Hata, M.; Hoshino, T.; Tsuda, M. Molecular dynamics study of HIV-1 Protease-substrate complex: Roles of the water molecules at the loop structures of the active site. J. Am. Chem. Soc., 2000, 122, 5613-5622. [31] Dunitz, J.D. The entropic cost of bound water in crystals and bio- molecules. Science, 1994, 264, 670. [32] Soroka, M.; Mastalerz, P. The synthesis of phosphonic and phosphinic analogs of aspartic acid and asparagine. Rocz. Chem., 1976, 50, 661-666. [33] Merrett, J.H.; Spurden, W.C.; Thomas, W.A.; Tong, B.P.; Whit- combe, I.W.A. The synthesis and rotational isomerism of 1-amino-
  • 7. Presentation of the -Carboxamidophosphonate Arrangement Letters in Drug Design & Discovery, 2009, Vol. 6, No. 2 145 2-imidazol-4-ylethylphosphonic acid [Phosphonohistidine, His(P)] and 1-amino-2- imidazol-2-ylethylphosphonic acid [Phosphonoiso- histidine, Isohis(P)]. J. Chem. Soc. Perkin Trans. I, 1988, 61-67. [34] Labelle, M.; Gravel, D. Unusually facile aminolysis of - ketoesters. J. Chem. Soc., Chem. Commun., 1985, 105-106. [35] Otera, J. Transesterification. Chem. Rev., 1993, 93, 1449-1470; and references cited. [36] Mottet, C.; Hamelin, O.; Garavel, G.; Depres, J-P.; Greene, A.E. A simple and efficient preparation of propargylic -ketoesters through transesterification. J. Org. Chem., 1999, 64, 1380-1382. [37] Gilon, C.; Klausner, Y.; Hassner, A. A novel method for the facile synthesis of depsipeptides. Tetrahedron Lett., 1979, 3811-3814; and references cited. [38] EC50 is the concentration required to achieve 50% protection of T4 lymphocyte (CEM-SS) from HIV-1 induced cytopathogenicity at 6 days post-infection, by XTT assay. Testing against HIV cytotoxic effects towards T4 lymphocytes was carried out in a high-flux screening programme; at National Cancer Institute, National Insti- tutes of Health, Bethesda, Maryland, 20892, USA: Wieslow, O.S.; Kiser R.; Fine, D.L.; Bader, J.; Shoemaker, R.H.; Boyd, M.R. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS- antiviral activity. J. Natl. Cancer Inst., 1989, 81, 577-586. [39] IC50 is the concentration required to inhibit HIV-1 PR activity by 50%. Testing against HIV-1 PR was carried out, courtesy of Dr. T. Lowinger, at Bayer AG, Pharma Research, D-42096 Wuppertal, Germany. [40] Bergmann, M.; Zervas, L. Über ein allgemeines verfahren der peptid-synthese. Ber. Dtsch. Chem. Ges., 1932, 65, 1192-1201. [41] Vogel, A.I. In Vogel’s Textbook of Practical Organic Chemistry (5th ed); Furniss, B.S.; Hanniford, A.J.; Smith, P.W.G.; Tatchell, A.R., Eds.; Longman Scientific and Technical, co-published with John Wiley and Sons: New York, 1989. [42] Thomsen, R.; Christensen, M.H. MolDock: A new technique for high-accuracy molecular docking. J. Med. Chem., 2006, 49, 3315- 3321. [43] Gehlhaar, D.K.; Verkhivker, G.; Rejto, P.A.; Fogel, D.B.; Fogel, L.J.; Freer, S.T. Docking conformationally flexible small molecules into a protein binding site through evolutionary programming. Pro- ceedings of the Fourth International Conference on Evolutionary Programming 1995, 615-627.